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CHAPTER I 
 
INTRODUCTION 
 
Voltage-gated sodium channels 
 Voltage-gated sodium channels (VGSCs) are a diverse family of proteins that are 
expressed mostly in excitable tissues and are responsible for the initiation and 
propagation of action potentials in muscle, nerve, and neuroendocrine cells. Upon 
activation, Na
+
 ions flow through the channel and into the cell, resulting in a rapid 
depolarization and the initial upstroke of the action potential. The family of VGSCs 
consists of nine genes encoding distinct pore-forming α subunits and four genes encoding 
accessory β subunits (Table 1) [1]. Though there are multiple subtypes of the α subunit, 
all are closely related with greater than 50% amino acid identity (Figure 1) [2]. The tissue 
specific expression of the various sodium channel isoforms and accessory proteins allows 
for regulation of channel activity and action potential morphology in various cell types.  
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Table 1. Summary of the different types of VGSCs and associated subunits. Adapted 
from Savio-Galimberti et al, 2012 [3] 
 
Gene 
 
Channel 
 
Expression 
 
TTX sensitivity 
       
SCN1A 
 
NaV1.1  
CNS, PNS 
 
S 
       
SCN2A 
 
NaV1.2  
CNS, PNS 
 
S 
       
SCN3A 
 
NaV1.3  
CNS, PNS 
 
S 
       
SCN4A 
 
NaV1.4  
Skeletal muscle 
 
S 
       
SCN5A 
 
NaV1.5  
Cardiac muscle 
 
R 
       
SCN8A 
 
NaV1.6  
CNS, PNS 
 
S 
       
SCN9A 
 
NaV1.7  
PNS, DRG 
 
S 
       
SCN10A 
 
NaV1.8  
PNS, DRG 
 
R 
       
SCN11A 
 
NaV1.9  
PNS, DRG 
 
R 
       
SCN6A / SCN7A 
 
NaX  
DRG / Heart / Uterus 
 
Unknown 
       
CNS, central nervous system; PNS, peripheral nervous system; 
DRG, dorsal root ganglia; S, sensitive; R, resistant 
       
Gene 
 
β subunit 
 
α subunit 
  
       
SCN1B 
 
β1 
 
NaV1.1 - NaV1.7   
       
SCN2B 
 
β2 
 
NaV1.1 - NaV1.2,   
    
NaV1.5 - NaV1.7   
       
SCN3B 
 
β3 
 
NaV1.1 - NaV1.3   
    
NaV1.5   
       
SCN4B 
 
β4 
 
NaV1.1, NaV1.2,   
    
NaV1.5   
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Figure 1. Amino acid sequence similarity of the α subunits of voltage-gated sodium 
channels NaV1.1-NaV1.9. Adapted from Catterall et al, 2005 [2]. 
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Structure and function of VGSCs 
 The pore-forming α subunit of the VGSC consists of four homologous 
transmembrane domains, DI – DIV, linked by intracellular loops (Figure 2A). Each 
domain consists of six transmembrane spanning segments (S1-S6), with the positively 
charged S4 serving as the voltage-sensor for the channel. The S4 region is critically 
involved in voltage-dependent activation while channel inactivation is controlled by the 
inactivation gate, formed by the intracellular loop connecting DIII-DIV, and the C-
terminal domain [4]. Ion selectivity and permeation are regulated by the extracellular 
pore loop between S5 and S6 [1].  
 VGSCs exist in three main functional states when expressed at the cellular 
membrane, depending upon the membrane potential (Figure 2B) [1]. A sudden membrane 
depolarization causes the S4 segments to move in an outward direction, causing a 
conformational change in the pore region that results in opening of the Na
+
 selective 
channel. Sodium ions entering an excitable cell cause rapid membrane depolarization and 
initiation of an action potential (Figure 2C). The process of sodium ions moving through 
open channels is transient, as the channel rapidly inactivates through gating processes 
involving the DIII-DIV linker, which quenches ion movement through the channel. Upon 
membrane repolarization, the channel recovers from the inactivated state and returns to a 
closed state where it is again ready to be activated by a subsequent depolarization. 
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Figure 2. Structure and function of VGSCs. (A) Graphical representation of the 
pore-forming α subunit and an accessory β subunit. (B) Functional channels exist in a 
closed, activated, or inactivated state. (C) Activation of VGSCs by a rapid 
depolarization opens the channel pore allowing Na
+
 to flow into the cell, further 
depolarizing the cell, before inactivating and eventually closing. Modified from 
George, 2005 {Formatting Citation}. 
α subunit β subunit
A 
B C 
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The role of VGSCs in cardiomyocyte physiology 
The cardiac action potential 
 The cardiac action potential is the result of multiple processes within 
cardiomyocytes (Figure 3). The cardiac sodium channel, NaV1.5, is responsible for the 
initial upstroke during Phase 0 of the human cardiac action potential. The Phase 1 notch 
is the result of the inactivation of the sodium channel and concurrent activity of ITO to 
remove K
+
 from the intracellular space. As a result of the rapid depolarization initiated by 
NaV1.5, L-type voltage-gated calcium channels activate and open, allowing Ca
2+
 to enter 
the myocyte, a step critical for excitation-contraction coupling. The plateau, or Phase 2, 
results from the balance of Ca
2+
 influx through calcium channels and K
+
 efflux through 
inward rectifying channels. Phase 3 occurs as calcium channels close and the inward 
rectifier K
+
 channels repolarize the cell and restores the membrane potential to resting 
values during Phase 4 [5]. 
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Figure 3. The cardiac action potential. A representative visualization of the cardiac 
action potential and the respective currents that control the morphology. Adapted from 
Grant, 2009 [5]. 
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Excitation – contraction coupling 
Proper function of the cardiac sodium channel is also critical for the 
cardiomyocyte to initiate contraction, as membrane depolarization is the first step in the 
process of excitation – contraction (EC) coupling. EC coupling is the process by which 
the electrical excitation of the myocyte is directly paired with the myocyte’s ability to 
contract through a mechanism triggered by the second messenger Ca
2+
 (Figure 4) [6]. The 
initial depolarization of the cardiomyocyte membrane by activation of NaV1.5 causes 
voltage-regulated L-type calcium channels to open and allows calcium to flow into the 
myocyte. Ca
2+
 entry is sensed by ryanodine receptors on the sarcoplasmic reticulum (SR) 
and, as a result, Ca
2+
 stored within the SR is released into the cytosol through calcium-
induced calcium release (CICR). Released calcium serves two main functions. One is 
inactivation of L-type ICa through direct feedback of localized [Ca
2+
] that helps to limit 
calcium influx during periods of high Ca
2+
 influx or SR release. The second function of 
CICR is to increase the levels of cytosolic Ca
2+
 in order to stimulate contraction of the 
myofilaments. Free cytosolic Ca
2+
 will bind to the myofilament protein Troponin C and 
initiate the contraction machinery. Myocytes will relax as cytosolic Ca
2+
 begins to 
dissipate. This is achieved by reuptake of Ca
2+
 into the SR through SERCA 
(sarco/endoplasmic reticulum Ca
2+
-ATPase) or removal through the sodium – calcium 
exchanger (NCX).  
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Figure 4. The role of calcium in the process of excitation – contraction coupling. 
Rapid depolarization of the ventricular myocyte activates voltage-gated L-type 
calcium channels and initiates EC coupling through the second messenger, Ca
2+
. Inset 
demonstrates the timing of the action potential, calcium transient, and resultant 
myocyte contraction. Adapted from Bers, 2002 [6]. 
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Regulation of intracellular sodium 
 In a human cardiomyocyte, intracellular sodium concentration is believed to be in 
the range of 4 – 10 mM while extracellular [Na+] is roughly 140 mM. The cardiomyocyte 
uses this Na
+
 gradient to drive multiple processes within the cell including proper 
calcium signaling, pH regulation, and cardiac metabolism (Figure 5) [7], [8]. 
 
Sodium – calcium exchanger (NCX) 
 As previously mentioned, the NCX is partially responsible for calcium regulation 
in the myocyte. NCX is capable of operating in both forward (Ca
2+
 extrusion) and reverse 
(Ca
2+
 influx) modes, depending on ion concentration gradients and membrane potential. 
Depolarization of the membrane by NaV1.5 hinders Ca
2+
 efflux at the start of the action 
potential, helping to stimulate CICR from the SR by limiting Ca
2+
 extrusion [9]. As the 
membrane potential begins to repolarize during systole, the forward mode of the NCX 
exchanges 3 extracellular Na
+
 ions for 1 intracellular Ca
2+
, producing an inward current 
that extends the plateau phase of the action potential. Removal of cytosolic Ca
2+
 through 
the forward mode of NCX contributes to relaxation of the contracted myocyte. During 
diastole, abnormal calcium release within a myocyte can activate the NCX and produce 
delayed afterdepolarizations (DADs) and is capable of triggering arrhythmias. 
 Modest increases in [Na
+
]i (a few mM) causes the NCX to extrude less Ca
2+
, 
effectively increasing [Ca
2+
]i, which is recovered by the SR. This loads the SR and can 
increase Ca
2+
 transients that intensify myocyte contraction. This is the mechanism of 
cardiac glycoside treatment (Digoxin, Ouabain, etc.) of congestive heart failure. By 
limiting extrusion of Na
+
i through inhibition of the Na
+
/K
+
-ATPase, [Na
+
]i is increased 
11 
 
and the resultant increase in [Ca
2+
]i loads the SR and increases inotropy. Excessive [Na
+
]i 
can result in the exchanger to operate in reverse, extruding sodium and driving Ca
2+
 into 
cells. Reverse mode of NCX is initiated by membrane depolarization and elevated levels 
of cytosolic Na
+
. This influx of Ca
2+
 can also load the SR and increase inotropy and, 
inadvertently, be arrhythmogenic [7]. 
 
pH regulation 
 The Na
+
 gradient is also coupled to regulation of intracellular pH through the 
Na
+
/H
+
 exchanger (NHE) and the Na
+
-HCO
-
3 cotransporter (NBC), which transport 
protons out and bicarbonate into the cell, respectively [7], [10], [11]. Both mechanisms 
are equally functional at an intracellular pH close to basal levels (pH 7.2). A decrease in 
pHi results in increased activity of both pathways and a resultant influx of Na
+
 into the 
cell. Activation of NHE is mainly through a drop in pH that promotes a rapid extrusion of 
acid. NBC is also regulated by pHi, however, its ability to buffer the cytosol is not as 
expansive as NHE. Increased levels of [Na
+
]i can have an impact on function of  these 
transporters, but not near the physiological Na
+
 levels. It is important to note, that during 
ischemia/reperfusion injury, the activity of NHE, and to a lesser extent, NBC, can 
increase [Na
+
]i to a point of forcing the NCX into reverse mode. The drug cariporide has 
been successfully used as a protective agent with respect to reperfusion injury [10] as 
well as instances of induced heart failure in a rabbit model [12]. 
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Cardiac metabolism 
 Intracellular Na
+
 is an important regulator of cardiac metabolism. Proper function 
of mitochondria rely upon activity of the mitochondrial NCX (NCLX) where [Na]i 
directly controls mitochondrial [Ca
2+
]. The NCLX is similar to the sarcolemmal NCX in 
which it exchanges 3 Na
+
 for 1 Ca
2+
 and is very sensitive to changes in [Na]i. Calcium 
enters the mitochondria through the calcium uniporter. At high workloads, Ca
2+
 uniporter 
activity is upregulated and increased [Ca
2+
]m stimulates further ATP production and 
enhances the maintenance of redox homeostasis. In conditions of high [Na
+
]i, such as 
reperfusion injury and heart failure, the NCLX increases activity with a concurrent 
removal of Ca
2+
m, increasing oxidative stress within the myocyte [7].  
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Figure 5. Sodium handling in the human heart. [Na
+
]i is influenced by many 
processes in the ventricular myocyte including action potential firing, pH regulation, 
and generation and recovery of Ca
2+
 transients. [Na
+
]i is maintained at proper levels in 
a healthy myocyte by extrusion through the Na
+
/K
+
 ATPase. Modified from Pieske et 
al, 2003 [8]. 
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Conduction of the cardiac impulse 
 Examining the fine details of the ventricular cardiomyocyte is extremely valuable 
and it affords a greater understanding of the intricacies associated with proper myocyte 
function. The delicate balance of ion concentrations and the processes that control them 
are impressive; however, it is important to examine the larger picture and understand how 
the contraction of one cardiomyocyte factors into the physiology of the heart. 
 The electrical impulse to initiate a contraction in a healthy heart originates in the 
sinoatrial (SA) node located in the wall of the right atrium (Figure 6) [13]. Cells within 
the SA node generate regular, spontaneous action potentials using calcium currents to 
produce the electrical activity. The action potential generated by the SA node is spread 
through the atria by cell-to-cell conduction. The wave of action potentials spreading 
across the atria depolarizes the atrial muscle and induces contraction through EC 
coupling. The depolarization of the atria is responsible for the P wave on an 
electrocardiogram (ECG) while repolarization occurs simultaneously with the QRS 
complex. 
 The electrical impulse quickly reaches the atrioventricular (AV) node located at 
the interatrial septum. The AV node also conducts action potentials by using Ca
2+
 
currents and is responsible for slightly slowing the electrical signal before the impulse is 
transmitted from the atria to the ventricles. The slight delay allows the atria to fully 
contract and push blood into the ventricles before the ventricles begin to contract. This is 
noted as the PR interval on the ECG.  
The impulse then reaches the bundle of His and follows the left and right bundle 
branches along the intraventricular septum. The signal is spread very rapidly along the 
15 
 
bundle branches, which eventually divide into a network of Purkinje fibers running 
throughout the ventricles. As the action potential passes through the Purkinje fibers, the 
electrical impulse is conducted to ventricular myocytes, initiating a concerted contraction 
through the ventricular walls which pumps blood into the aorta and pulmonary artery. 
The QRS complex seen on a typical ECG represents depolarization of the left and right 
ventricles while the T wave represents repolarization. Abnormalities in any part of the 
ECG can indicate a potential disease state, including those caused by mutations in 
NaV1.5, such as long QT and Brugada syndromes. 
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Figure 6. The cardiac conduction system. The electrical signal that initiates 
conduction begins in the SA node and rapidly spreads through the right (RA) and left 
(LA) atria. The impulse passes through the AV node, along the left and right bundle 
branches, and stimulates firing of purkinje fibers. The action potential is then 
propagated throughout the ventricles. Shown are action potential characteristics 
associated with different parts of the conduction system. The differing firing properties 
allow for specific control and timing of the impulse over the heart. Modified from 
Munshi 2012 [13]. 
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Diseases associated with NaV1.5 mutations 
 The cardiac sodium channel NaV1.5 is responsible for the influx of Na
+
 that drives 
initiation of the action potential. Regulation of the sodium current, INa, is critical as 
changes in current density or activation and inactivation patterns can have detrimental 
consequences. Most cardiac channelopathies, including those caused by NaV1.5 
mutations, are arrhythmogenic as they alter the balance of currents shaping the action 
potential or they affect how the action potential conducts across the heart. 
 Inherited arrhythmia syndromes such as long QT syndrome (LQTS) may have 
altered action potential morphology. Most cases of LQTS associated with NaV1.5 
mutations are a result of defective inactivation that allows Na
+
 to continually pass 
through NaV1.5 channels without fully inactivating (Figure 7A). This causes an 
elongation of the plateau phase of the cardiac action potential and delays repolarization 
(Figure 7B). This lengthens the action potential duration and the QT interval measured on 
the ECG. Ventricular arrhythmias can manifest through early afterdepolarizations as a 
result of calcium channel reactivation during the prolonged plateau of the action 
potential, creating a depolarized region that is capable of stimulating regions of the heart 
that have already repolarized. Early afterdepolarizations can result in reentrant 
arrhythmias and may trigger torsades de pointes, a form of polymorphic ventricular 
tachycardia in which the electrical axis rotates and the amplitude of the QRS complex 
oscillates in a sinusoidal pattern [14]. Torsades occurs when ventricular depolarization 
(signified by the QRS complex) is triggered late in diastole during the repolarization 
phase (T wave) [15]. It is important to note that milder forms of LQTS can be 
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exacerbated by medications that prolong the action potential, such as drugs that block IKr 
(hERG channel). 
 Brugada syndrome (BrS) has been associated with almost 100 mutations in the 
cardiac sodium channel gene, SCN5A [16]. Most SCN5A mutations in BrS result in a 
loss-of-function, predicting reduced myocardial INa density. Two mechanisms have been 
proposed to explain the cellular basis of BrS [17]. One mechanism suggests that reduced 
INa results in unopposed ITO, disproportionate shortening of epicardial action potentials 
and an exaggerated transmural voltage gradient resulting in a substrate susceptible to 
potentially lethal reentrant arrhythmias (Figure 8) [1], [17].  The second mechanism 
proposes that reduced INa causes slowing of impulse conduction in the right ventricle and 
a delayed activation of the right ventricular outflow tract (RVOT) [18]. This causes the 
membrane potential of the RVOT to become more positive compared to the right 
ventricle and can trigger reentry arrhythmias as the RVOT now acts as a source of current 
instead of a sink. 
 Cardiac conduction disease (CCD) has also been attributed to SCN5A mutations. 
CCD is a potentially life threatening disorder of the heart where the function of the 
conduction system is impaired. This can result in a slowing or complete blockage of 
impulse conduction and may cause life-threatening rhythm disturbances [19]. The role 
that mutations in NaV1.5 have are complex; however, mutations causing isolated 
conduction defects have generally been observed to cause reduced channel availability as 
a consequence of mixed gating disturbances [1]. Treatment for CCD is implantation of a 
mechanical pacing device in order to stimulate the appropriate regions of the heart in a 
time-dependent cycle. 
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  A 
B 
Figure 7. Persistent INa contributes to LQTS. (A) Mutations in NaV1.5 that impair 
inactivation, such as delKPQ, can result in persistent current that can elongate the 
cardiac action potential. (B) The extended time course of the action potential lengthens 
the depolarization and repolarization cycle of the ventricles and causes a concurrent 
lengthening of the QT interval. Adapted from George, 2005 [1]. 
Persistent INa
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Figure 8. Brugada syndrome as a result of reduced INa. Modified from George, 
2005 [1]. 
21 
 
Heart failure and the cardiac sodium channel 
 A new subset of mutations has been identified that expand the clinical spectrum 
of sodium channelopathies to disease states resulting in a cardiomyopathic phenotype. In 
2004, McNair et al provided the first glimpse into NaV1.5-associated heart failure, 
describing the mutation D1275N segregated in a large family with conduction disorder 
and dilated cardiomyopathy [20]. Shortly thereafter, Olson et al analyzed a cohort of 
patients diagnosed with idiopathic dilated cardiomyopathy and identified a small number 
of NaV1.5 mutations, including the already mentioned D1275N and the novel voltage 
sensor mutation R814W [21]. Multiple cardiomyopathy mutations have since been 
identified that cluster within voltage sensing regions of NaV1.5 [22]. Critical analysis has 
revealed that mutations of arginine residues in the S4 regions of DI and DII of NaV1.5 
(R219H, R222Q, and R814W) have resulted in a similar form of heart failure, typically 
diagnosed as dilated cardiomyopathy. 
Mutations in voltage sensing region of DI and DII have been identified to alter 
gating charges and can shift the channel’s inherent sensitivity to changes in membrane 
potential. In 2006, our lab characterized R814W and noted significant changes to 
window-currents and ramp-currents that indicate this mutant channel activates at 
hyperpolarized potentials compared with wild-type channel, signifying possible channel 
openings during diastole [23]. Biophysical analysis of R222Q revealed a similar pattern 
of hyperpolarized window- and ramp-currents, however, the complexity of the clinical 
outcome is extensive and those individuals with this mutation present with multiple 
arrhythmias linked to Purkinje system dysfunction and heart failure often in the form of 
dilated cardiomyopathy [24], [25]. Many of these patients were successfully treated with 
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quinidine, which often resulted in a decrease in PVCs and a recovery of heart function, 
consistent with previous publications indicating treatment of PVCs improves left 
ventricular function (Figure 9).  
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Figure 9. Cardiac sodium channel mutations associated with heart failure. The 
mutations R222Q and R814W are located in the voltage-sensing regions of domains I 
and II, respectively. Activation properties are shifted to a hyperpolarized state, thus 
increasing the window current seen in panels A and B. Panel C shows a larger 
hyperpolarized peak during a slow ramp current compared with WT channels. 
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Project summary and specific aims 
The aim of this thesis is to identify and characterize cardiac sodium channel 
(NaV1.5) mutations associated with heart failure phenotypes. We present biophysical 
analysis of multiple mutations, including the novel mutation, R225P, with similarly 
hyperpolarized window- and ramp-currents in order to identify a potential indicator for 
the progression of heart failure.  
 
Part I: Characterization of cardiac sodium channel mutation NaV1.5-R225P 
Previous research on cardiac sodium channel mutations have revealed specific 
channel properties that correlate directly to disease states, such as persistent current 
leading to LQT syndrome. Here, we identify a hyperpolarized ramp current as a shared 
functional consequence of mutations that result in a heart failure phenotype. Two 
mutations resulting in similar cardiomyopathies, NaV1.5-R814W and NaV1.5-R222Q, 
have been previously identified and characterized [21], [23]–[28]. We corroborated the 
biophysical findings with our own data on these mutations and compared them to a novel 
missense mutation, NaV1.5-R225P, found in a patient with amiodarone-responsive 
ventricular ectopy and impaired contractility. Interestingly, biophysical characterization 
of these 3 mutations showed similarly altered channel activation with a larger, 
hyperpolarized ramp current compared to wild type channels. We propose that this ramp 
current defect could be a biophysical fingerprint for those mutations with a propensity for 
cardiomyopathies.  
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Part II: Analysis of NaV1.5 mutations in an isolated, virally-transduced ventricular 
cardiomyocyte 
Mutations in the human heart sodium channel most often cause disorders 
affecting cardiac rhythm.  However, recent research has identified multiple mutations in 
NaV1.5 associated with a heart failure phenotype.  This unexpected association creates an 
expanded clinical spectrum of conditions associated with cardiac sodium channelopathies 
and establishes a need to elucidate the link between cardiac Na channel dysfunction and 
cardiomyopathies. 
Intracellular ion homeostasis in cardiomyocytes is tightly regulated by multiple 
exchangers and transporters that directly couple Na
+
 to important cellular processes such 
as calcium removal via the Na
+
/Ca
2+
 exchanger (NCX) and regulation of intracellular pH 
through the Na
+
/H
+
 exchanger (NHE).  Previous data predicts that the mutations NaV1.5-
R814W and NaV1.5-R222Q allow for an inappropriate influx of Na
+
 during diastole 
which has the potential of disturbing intracellular Ca
2+
 and H
+
 dynamics leading to 
myocardial failure.  The objective of this section is to establish a relationship between 
sodium channel dysfunction and impaired contraction as a consequence of altered Ca
2+
 
and/or pH homeostasis in cardiac myocytes. 
 
Specific aims 
Specific aim 1. To characterize the novel cardiac sodium channel mutation NaV1.5-
R225P in comparison to wild type channel and previously identified mutations 
associated with cardiomyopathy. Mutations to critical arginine residues in the voltage 
sensing region of NaV1.5 (R814W and R222Q) have been previously identified and 
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exhibit similar heart failure phenotypes and comparable biophysical characteristics. 
Because the novel mutation R225P has a similar clinical phenotype and mutates a critical 
arginine in the S4 region, I hypothesized that biophysical characterization of the 
mutation NaV1.5-R225P would reveal a hyperpolarized window-current with a 
large, hyperpolarized ramp-current similar to that seen in R814W and R222Q.  
 
Specific Aim 2. To determine if mutant Na
+
 channel expression in myocytes alters 
intracellular Ca
2+
 handling. I hypothesized that human mutant Na
+
 channel expression 
alters Ca
2+
 handling within isolated ventricular cardiomyocytes.  I predicted that excess 
intracellular Na
+
 would limit the ability of the NCX to extrude cytosolic calcium which 
will result in aberrant calcium levels during systole and diastole.  To test this, I expressed 
the mutant Na
+
 channel in rabbit cardiomyocytes and examined calcium levels during 
pacing using fluorescent dyes.  I expected to see altered calcium kinetics and an increase 
in basal and peak Ca
2+
 levels. 
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CHAPTER II 
 
NOVEL SCN5A MUTATION IN AMIODARONE-RESPONSIVE MULTIFOCAL 
VENTRICULAR ECTOPY-ASSOCIATED CARDIOMYOPATHY 
 
Introduction 
The voltage-gated cardiac sodium channel NaV1.5 encoded by SCN5A is 
responsible for the initial upstroke of the cardiac action potential [17]. Mutations in 
SCN5A typically manifest as cardiac arrhythmias such as the congenital long-QT or 
Brugada syndromes, or by variable degrees of impaired cardiac conduction. Importantly, 
some SCN5A mutations are associated with clinical features that overlap more than one 
disorder [29]. Additionally, a new genotype-phenotype correlation has emerged recently 
that has expanded the clinical spectrum of sodium channelopathies to include disorders 
which feature impaired cardiac contractility. 
In 2004, McNair et al. described a multigenerational family segregating SCN5A-
D1275N with a complex disorder featuring variable combinations of supraventricular 
arrhythmias, impaired atrioventricular conduction and dilated cardiomyopathy [20]. 
Shortly thereafter, Olson et al. screened a cohort of patients diagnosed with idiopathic 
dilated cardiomyopathy and identified five SCN5A mutations including a novel voltage 
sensor mutation (R814W) [21]. Subsequent functional studies of R814W revealed a novel 
pattern of sodium channel dysfunction featuring a prominent defect in the voltage-
dependence of activation [23]. Two other SCN5A voltage sensor mutations associated 
with cardiomyopathy and variable arrhythmias have been identified (R219H, R222Q) 
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[22], [24]–[26], [28], [30]. The R222Q mutation exhibits many of the same biophysical 
abnormalities as R814W, whereas R219H appears to have a distinct functional 
perturbation (gating pore leak current). Importantly, the clinical syndrome associated 
with some of these mutations, best illustrated for R222Q, exhibits reversibility of 
contractile dysfunction with antiarrhythmic therapy [24]. However, the pharmacological 
mechanism responsible for this effect has not been explored. 
Here, we present a novel SCN5A mutation (NaV1.5-R225P) associated with 
prenatal arrhythmias, impaired cardiac contractility, and postnatal multifocal ventricular 
ectopy-associated ventricular dysfunction reversed by amiodarone treatment. We 
elucidated the functional consequences of the mutation and demonstrated the likely 
mechanism for amiodarone efficacy. These findings extend the phenotypic spectrum of 
SCN5A mutations and reveal a plausible pharmacological mechanism underlying the 
reversibility of arrhythmia-associated cardiomyopathy.  
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Materials and Methods 
 
Subject Ascertainment 
The mother of the proband volunteered her son’s clinical history and genetic 
information without solicitation. Subsequently, informed consent was obtained to 
evaluate medical record information including genetic testing data. The informed consent 
procedure was approved by the Vanderbilt University Institutional Review Board. 
Genetic testing for mutations in KCNQ1, KCNH2, SCN5A, KCNE1, KCNE2 and KCNJ2 
was performed by The Scottish Genetics Laboratory, Aberdeen. 
  
Cloning and expression of NaV1.5 
A cDNA encoding human NaV1.5 was cloned into the bicistronic vector pRc-
CMV_IRES2-CD8 and mutations were created using site-directed mutagenesis. Human-
derived tsA201 cells (HEK293 cell line expressing SV40 large T antigen) were 
transiently transfected with 1.0 g of WT or mutant NaV1.5 plasmid using FuGeneHD 
(Roche Diagnostics, Indianapolis, IN) in combination with 0.6 g of a bicistronic plasmid 
(pIRES-GFP-hβ1) encoding enhanced green fluorescent protein (GFP) and the human β1 
subunit (hβ1) under the control of the CMV immediate early promoter. Positively 
transfected cells were determined by GFP emission and the binding of beads conjugated 
with anti-CD8 antibodies. 
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Electrophysiology 
Sodium currents were recorded at room temperature (22-23°C) 48-72 hours after 
transfection using the whole-cell patch clamp technique as previously described [23]. All 
data were analyzed using pCLAMP 10.0 or Microsoft Excel 2007 and plotted using 
SigmaPlot 10.0 (Systat Software, Inc., San Jose, CA). Statistical analysis was performed 
using Student’s t-Test. 
Experiments examining persistent INa and ramp-currents utilized tetrodotoxin 
(TTX; Tocris Bioscience, Bristol, UK) to allow for the determination of TTX-sensitive 
sodium current. TTX was added to the bath solution from a stock solution of TTX (3 mM 
in water) to a final concentration of 30 µM. TTX-sensitive current was determined by 
offline digital subtraction.  
 
Pharmacology 
Amiodarone hydrochloride (Sigma-Aldrich, St. Louis, MO) was dissolved in 
dimethyl sulfoxide (DMSO; Sigma-Aldrich) to create a stock concentration of 30 mM. 
For experiments, amiodarone stock was diluted into bath solution for use at 3 µM 
concentration. Fresh dilutions were made on the day of experiments. Amiodarone or 
DMSO was continually present in the superfusate during experiments examining the 
biophysical effects of amiodarone. DMSO concentration never exceeded 0.01% in 
control or test conditions.  
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Results 
 
Case Presentation 
A Caucasian male was delivered at 37 weeks gestation following an eventful 15 
week antenatal course. Fetal tachycardia accompanied by poor ventricular function was 
noted at 22 weeks. Maternal flecainide administration was initiated at 27 weeks. At 28 
weeks, fetal tachycardia with 2:1 atrioventricular (AV) conduction was noted and 
suggested a supraventricular origin of the arrhythmia. Tachycardia persisted despite 
escalating the dosage of flecainide. Propranolol was added at 31 weeks and fetal heart 
rate normalized with concomitant improvement in ventricular function. A maternal 
flecainide/propranolol regimen was maintained through parturition.  
Immediately following birth, a wandering atrial rhythm at 137 bpm with frequent, 
multifocal ventricular ectopic beats was noted (Figure 10A, Figure 11A). Treatment with 
amiodarone (5 mg/kg initially three times daily for one week, then twice daily for one 
week followed by a maintenance dose of amiodarone 5 mg/kg daily) in combination with 
propranolol (1 mg/kg four times daily; 3 mg four times daily absolute dose) was initiated.  
Continued atrial and ventricular ectopy was evident at age 1 month, and an ECG obtained 
at 7 weeks showed atrial tachycardia (atrial rate 260 bpm) with 2:1 AV block (Figure 
10B, Figure 11B). The antiarrhythmic regimen was not changed. By 3 months of age, an 
ECG was reported as showing predominantly sinus rhythm with some ectopy (trace not 
available). Because of persistent sinus rhythm at age 6 months, amiodarone was 
discontinued while propranolol was continued (3 mg four times daily). Two weeks after 
stopping amiodarone, an ECG showed sinus rhythm but with a prolonged QTc interval of 
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480 msec (Figure 10C, Figure 11C). Propranolol was discontinued at that time. However, 
he was hospitalized 6 weeks later with supraventricular tachycardia (200 bpm) and 
multifocal ventricular ectopy (Figure 10D, Figure 11D). Echocardiography demonstrated 
impaired ventricular function (ejection fraction 43%, fractional shortening 17%; Figure 
12). Amiodarone was restarted with an initial loading dose followed by a maintenance 
dose of 5 mg/kg/day. Propranolol was reinstituted at a dose of 1 mg/kg four times daily 
and he was started on captopril 0.5 mg/kg three times daily. This regimen suppressed 
abnormal rhythms (Figure 10E, Figure 11E) and there was improvement in ventricular 
function albeit with an unexplained change in P wave morphology as compared to age 
6.5 months (Figure 10C). Subsequent attempts to replace amiodarone with sotalol were 
unsuccessful with recurrence of tachycardia, increased frequency of ventricular ectopy 
and one episode of nonsustained ventricular tachycardia. There were no documented 
episodes of ventricular arrhythmia that resembled torsades de pointes. At age 6 years, the 
proband remained on amiodarone but propranolol was substituted with nadolol. There 
have been rare syncopal events, no occurrences of cardiac arrest, but mild growth 
retardation was noted. Invasive electrophysiological testing was not performed.  
There is no family history of cardiac arrhythmia or sudden unexplained death. 
Both parents and an older female sibling are healthy with normal heart rhythms and 
normal ECG indices including normal QTc intervals. Genetic testing of the proband 
revealed a novel missense mutation in SCN5A predicting the substitution of arginine at 
position 225 with proline (R225P). Neither parent nor the sibling carried this variant, 
consistent with a de novo mutation in the proband. 
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Figure 10. Electrocardiograms from the proband. (A) Representative lead II 
recording obtained at age 3 days illustrating wandering atrial rhythm with frequent 
multifocal premature ventricular beats. (B) Representative lead II recording obtained 
at age 7 weeks illustrating an episode of supraventricular tachycardia with variable 2:1 
and 3:1 AV block. (C) Representative lead II recording obtained at age 6.5 months 
two weeks off amiodarone illustrating sinus rhythm with a prolonged QTc (480 ms). 
(D) Representative lead II recording obtained at age 9 months while the proband was 
off antiarrhythmic drugs illustrating multifocal ventricular ectopy and two 3-4 beat 
runs of nonsustained ventricular tachycardia. (E) Representative lead II recording 
obtained at age 20 months while treated with amiodarone and propranolol illustrating 
sinus rhythm. More complete ECG recordings corresponding to each of these events 
are provided as Figure 11. 
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A.  Age 3 days 
B.  Age 7 weeks 
C.  Age 6.5 months 
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D.  Age 9 months 
E.  Age 20 months 
Figure 11. Additional electrocardiographic recordings of the proband.  
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Figure 12. Echocardiographic images of the proband (weight 8.4 kg, height 69 
cm) illustrating dilation of all cardiac chambers. 
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Functional properties of NaV1.5-R225P  
We compared the functional properties of WT and R225P mutant cardiac sodium 
channels (NaV1.5) heterologously expressed in tsA201 cells with the human 1 subunit 
(Figure 13). Cells expressing R225P exhibited significantly greater current density and 
appeared to activate at more hyperpolarized potentials than WT channels (Figure 13A,B). 
Boltzmann fits of the conductance-voltage plots revealed similar voltage dependence of 
activation for WT and R225P (V½ values: WT, -37.3±0.06 mV; R225P, -37.1±1.0) but 
R225P exhibited a significantly shallower slope (WT: 8.4±0.2, R225P: 12.3±0.3; 
p<0.005; Figure 13C; Table 2) suggesting a blunted voltage sensitivity. Activation 
kinetics, as determined by the time-to-peak current at an activating potential of -20mV, 
were also significantly altered in the mutant channel (R225P: 0.96±0.01 ms; WT: 
0.67±0.02 ms; p<0.005; Figure 14A; Table 2). These findings were consistent with a 
structural perturbation of the domain 1 voltage-sensor segment that disrupts channel 
activation. 
In addition to abnormalities in activation, inactivation of R225P channels was also 
abnormal (Figure 13D). Time constants for inactivation determined by fitting current 
decay with a double exponential function were significantly larger for R225P channels 
across a range of voltages compared to WT channels indicating slower inactivation 
(Figure 13E). Additionally, the mutant channels exhibited a significantly larger fraction 
of current inactivating with a slow component (time constant 2; Figure 14B). Cells 
expressing R225P also had a significantly larger persistent current measured as a 
percentage of peak current (0.87±0.06%, n=10) compared to WT channels (0.13±0.02%, 
n=18; p<0.005; Figure 13F; Table 2). This level of increased persistent current was 
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similar to what we observed in parallel experiments for an LQTS-associated mutant 
NaV1.5 channel (delKPQ: 0.65±0.04%, n=8; Table 2) [31]. By contrast, the voltage 
dependence of steady-state inactivation (channel availability) and the time course of 
recovery from fast inactivation of R225P were not overtly different from WT channels 
(Figure 14C,D; Table 2). Although the voltage midpoints (V½ values) for activation and 
inactivation were not affected by the mutation, the more shallow activation curve slope 
caused a significantly expanded ‘window current’ defined as the extent of overlap 
between the two curves (Figure 15A). This suggests that the R225P mutation could evoke 
aberrant sodium current activation at voltages within the window.  
The potential for aberrant sodium current activation was further probed by 
examining channel responses to depolarizing voltage ramps. Comparing R225P ramp-
currents to those of WT channels revealed critical differences in magnitude and kinetics. 
For R225P, averaged ramp currents exhibit activation with a broad, nearly bifid peak at 
significantly more hyperpolarized potentials than WT channels (Figure 15B; Table 2). 
Net charge movement during voltage ramps was 8-fold greater for R225P than WT 
channels (WT: 0.66±0.1 pC/nA, R225P: 5.86±0.6 pC/nA; p<0.005) (Figure 16; Table 2). 
These findings indicate that aberrant sodium current conducted by R225P channels can 
be evoked by voltages close to the resting membrane potential of cardiomyocytes.  
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Figure 13. Biophysical properties of NaV1.5-R225P.  (A) Representative traces of 
WT (top) and R225P (bottom) sodium channels. (B) Current-density/voltage plots of 
WT and R225P. (C) Voltage dependence of activation for WT and R225P from -80 to 
+20 mV. (D) Representative traces of WT and R225P illustrating altered activation 
and inactivation kinetics. (E) Voltage-dependence of inactivation time constants (open 
symbols represent fast component; closed symbols represent slow component) for WT 
and R225P. (F) Representative TTX-subtracted whole cell current for WT and R225P. 
Persistent current was measured over the final 10 ms of a 200 ms pulse to -20 mV and 
normalized to peak current. Inset shows persistent current over the final 50 ms. All 
data are represented as mean ± S.E.M for n=11-18 cells.  
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Figure 14. Activation and inactivation of R225P. (A) Activation kinetics measured 
as time to peak current derived from activating pulses to -20mV (holding potential -
120 mV) for WT and mutant channels. (B) Percentage of current inactivation 
associated with the slow component (time constant, τ2) of current decay for WT and 
R225P. (C) Channel availability of WT and R225P. (D). Recovery from fast 
inactivation. All data are represented as mean ± S.E.M. for n= 8 - 9 cells. 
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Figure 15. Window and ramp-currents of NaV1.5-R225P reveal aberrant INa at 
hyperpolarized potentials. (A) Overlay of Boltzmann-fitted G/V and channel 
availability curves of WT and R225P emphasizing window-currents. (B) Normalized 
TTX-subtracted average ramp-currents (0.32 mV/ms) of WT and R225P measured as 
a percentage of peak INa (-20mV). All data are represented as mean ± S.E.M for n=7-
15 cells. 
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Figure 16. Ramp-current analysis. Net charge movement during slow voltage-ramps 
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Table 2. Biophysical properties of WT-NaV1.5 and mutant channels. 
 
  
  
WT R225P R222Q 
Activation 
V½ -37.3 ± 0.6 -37.1 ± 1.0 -51.2 ± 1.5** 
k 8.4 ± 0.2 12.3 ± 0.3** 7.6 ± 0.4 
n 14 11 13 
     
Inactivation 
V½ -86.0 ± 0.4 -86.8 ± 0.6 -92.7 ± 0.8** 
k -6.4 ± 0.1 -6.3 ± 0.1 -5.6 ± 0.1** 
n 11 10 14 
     
Window-
current peak 
Voltage -60.4 ± 0.4 -67.0 ± 1.2** -74.7 ± 0.4** 
Activity 0.037 ± 0.001 0.063 ± 0.002** 0.050 ± 0.002** 
n 10 7 8 
     
Time to peak  
(-20 mV) 
Peak (ms) 0.67 ± 0.02 0.96 ± 0.01** 0.56 ± 0.01** 
n 18 10 7 
     
Recovery from 
fast inactivation 
A1 0.85 ± 0.01 0.90 ± 0.01* 0.87 ± 0.02 
1 6.5 ± 0.3 6.2  ± 0.3 7.0 ± 0.3 
A2 0.15 ± 0.01 0.10 ± 0.01** 0.14 ± 0.02 
2 178 ± 18 147 ± 14 153 ± 17 
n 18 9 10 
     
500ms Ramps 
Peak (mV) 45.7 ± 2.7 -57.1 ± 3.0* -70.9 ± 0.9** 
% peak -0.60 ± 0.04 -4.9 ± 0.3** -1.0 ± 0.1** 
Area (pC/nA) 0.66 ± 0.1 5.86 ± 0.6** 0.89 ± 0.1 
n 15 11 8 
     
Ramp-current 
activation 
threshold 
    
Voltage -77.2 ± 1.2 -96.5 ± 1.2** -97.3 ± 1.6** 
n 13 16 8 
    
     
Persistent INa 
% peak 0.13 ± 0.02 0.87 ± 0.06** 0.09 ± 0.03 
n 18 10 7 
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R814W R225Q delKPQ 
Activation 
V½ -41.1 ± 1.6* -40.2 ± 0.7* -28.4 ± 1.2** 
k 10.7 ± 0.4** 9.8 ± 0.2** 10.4 ± 0.1** 
n 15 13 12 
     
Inactivation 
V½ -84.9 ± 0.8 -90.2 ± 0.6** -92.5 ± 0.8** 
k -6.5 ± 0.2 -6.6 ± 0.2 -5.6 ± 0.1** 
n 14 10 14 
     
Window-
current peak 
Voltage -65.3 ± 0.9** -65.6 ± 0.7** -60.7 ± 1.5 
Activity 0.064 ± 0.003** 0.038 ± 0.002 0.025 ± 0.002** 
n 12 11 10 
     
Time to peak 
 (-20 mV) 
Peak (ms) 0.66 ± 0.02 0.75 ± 0.03* 0.53 ± 0.02** 
n 7 14 8 
     
Recovery from 
fast inactivation 
A1 0.88 ± 0.01 0.85 ± 0.02 0.86 ± 0.02 
1 6.8 ± 0.5 7.8 ± 0.7 4.9 ± 0.2** 
A2 0.11 ± 0.01* 0.15 ± 0.02 0.14 ± 0.02 
2 190 ± 29 209 ± 289 265 ± 49 
n 8 8 10 
     
500ms Ramps 
Peak (mV) -64.9 ± 1.4** -56.7 ± 3.4* -35.0 ± 1.9* 
% peak -2.4 ± 0.1** -0.9 ± 0.1** -1.0 ± 0.1** 
Area (pC/nA) 2.17 ± 0.2** 1.01 ± 0.2 1.71 ± 0.2** 
n 7 12 8 
     
Ramp-current 
activation 
threshold 
    
Voltage -95.4 ± 2.3** -86.42 ± 1.6** -68.5 ± 1.2** 
n 7 11 7 
    
     
Persistent INa 
% peak 0.17 ± 0.03 0.24 ± 0.03* 0.65 ± 0.04** 
n 7 14 8 
     
   
Versus WT  
   
* = P < 0.05 
   
** = P < 0.005 
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Altered slow inactivation of R225P channels 
To further investigate the functional consequences of R225P, we examined the 
sensitivity of the mutant channel to frequency-dependent inhibition. Stimulating at 2 Hz 
with a 5 ms test pulse, we did not identify a difference in current amplitude between WT 
and R225P following 100 pulses (Figure 17A, Figure 18A; Table 3). However, at pulse 
lengths of 100 ms and 300 ms, there was a significant divergence in current amplitude for 
WT and R225P at pulse 100, with the mutant channel exhibiting a greater sensitivity to 
the frequency-dependent protocol. This dependence on the pulse duration without an 
overt difference in recovery from fast inactivation suggested possible involvement of 
enhanced slow inactivation to explain the greater activity-dependent loss of channel 
availability observed for R225P.  
We compared the slow inactivation properties of WT and R225P channels. As 
illustrated by Figure 17B and data in Table 3, both WT and R225P channels enter slow 
inactivation with similar rates during conditioning pulses up to 3000 ms. However, for 
conditioning pulse durations longer than 3000 ms, the behavior of WT and R225P 
channels diverge, with R225P showing enhanced entry into a slow inactivated state. 
Using a 3000 ms test pulse (approximate midpoint for onset of slow inactivation for both 
WT and R225P), we measured recovery from slow inactivation (Figure 17C, Table 3). 
The biexponential time course of recovery from slow inactivation observed for R225P 
was significantly slower than WT channels. Further, we observed that the voltage-
dependence of slow inactivation was significantly shifted in the hyperpolarized direction 
for R225P compared with WT channels (Figure 17D, Table 3). Collectively, these 
findings indicate that the R225P mutation stabilizes the slow inactivated state and 
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enhances the tendency for slow inactivation. To determine whether this enhanced slow 
inactivation might affect the ramp current, we examined channel availability following a 
series of ramp depolarizations (500 ms ramps; 1.1 Hz). There was a significant decrease 
in charge movement at pulse 100 for R225P but not WT channels. Despite this effect of 
repetitive pulsing, charge movement associated with voltage ramps remained greater for 
R225P than WT channels (Figure 19; Table 3).  
 
  
48 
 
  
 
  
Pulse duration (ms)
0 50 100 150 200 250 300N
o
rm
a
liz
e
d
 c
u
rr
e
n
t 
(P
1
/P
1
0
0
)
0.0
0.2
0.4
0.6
0.8
1.0
1.2
WT 
R225P 
A
-120 mv
-20 mv
Δ ms
Recovery period (ms)
1 10 100 1000 10000 100000
N
o
rm
a
liz
e
d
 c
u
rr
e
n
t
0.0
0.2
0.4
0.6
0.8
1.0
WT 
R225P 
-120 mv
-20 mv
3s
Δms
C
Voltage (mV)
-120 -100 -80 -60 -40 -20 0
N
o
rm
a
liz
e
d
 c
u
rr
e
n
t
0.0
0.2
0.4
0.6
0.8
1.0
WT
R225P
-120 mv
-20 mv
3s 50ms
0 mv
D
Pulse duration (ms)
1 10 100 1000 10000 100000
N
o
rm
a
liz
e
d
 c
u
rr
e
n
t
0.0
0.2
0.4
0.6
0.8
1.0
WT
R225P
-120 mv
-20 mv
Δ ms
50ms
**
B
**
Figure 17. NaV1.5-R225P stabilizes the slow-inactivated state. (A) Frequency-
dependent channel inhibition of WT (black) and R225P (red) observed for activating 
pulse durations of 5, 100, and 300 ms. Curves were fit with exponential decay 
functions. (B) Onset of slow inactivation for WT and R225P. (C) Recovery from slow 
inactivation. WT (black line) and R225P (red line) data fit with double-exponential 
curves. (D) Voltage-dependence of slow-inactivation of WT and R225P. Curves are 
the result of data fittings with the Boltzmann function. All data are represented as 
mean ± S.E.M for n=7-15 cells. 
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Figure 18. Frequency-dependent inhibition. Pulse trains (2Hz; -20mV) illustrated 
for WT (black) and R225P (red) channels with activating pulses of 5 ms (open 
circles), 100 ms (open triangles), or 300 ms (open square). All data are represented as 
mean ± S.E.M. for n = 11 - 15 cells. 
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Figure 19. Ramp-current analysis. Charge movement in response to consecutive 500 
ms ramp-current protocols (1.1 Hz; 100 pulses). All data are represented as mean ± 
S.E.M. for n = 7 - 16 cells. 
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Table 3. Frequency-dependent inhibition and slow inactivation properties of WT-
NaV1.5 and R225P. 
 
 
  
  
WT 
 
R225P 
 
  
     
Frequency 
dependent 
inhibition 
2 Hz 
5 ms 
pulse length 
P1/P100 1.01 ± 0.01  
1.03 ± 0.01* 
n 11 
 
12 
  
     
100 ms pulse 
length 
P1/P100 0.93 ± 0.01  
0.69 ± 0.02** 
n 15 
 
15 
  
     
300 ms pulse 
length 
P1/P100 0.80 ± 0.02 
 
0.47 ± 0.02** 
n 14 
 
12 
 
  
     
Onset of slow 
inactivation 
  
 
A1 0.21 ± 0.03 
 
0.21 ± 0.04 
  
 1
 314.1 ± 41.5 
 
373.3 ± 81.5 
  
 
A2 0.45 ± 0.04 
 
0.7 ± 0.04** 
  
 2
 9973.5 ± 1601.2 
 
10321.1 ± 224.5 
  
 
y0 0.32 ± 0.02 
 
0.08 ± 0.003** 
  
 
n 8 
 
7 
 
  
     
Recovery 
from slow 
inactivation 
(3s pre-pulse) 
  
 
A1 0.69 ± 0.01 
 
0.63 ± 0.02* 
  
 1
 10.1 ± 0.9 
 
14.0 ± 1.1* 
  
 
A2 0.31 ± 0.01 
 
0.35 ± 0.02 
  
 2
 352.3 ± 24.4 
 
2261.9 ± 
251.8**   
 
n 9 
 
9 
 
  
     
Voltage 
dependence of 
slow 
inactivation 
  
 
V½ -68.9 ± 5.2  
-83.5 ± 0.8* 
  
 
k -32.9 ± 2.2 
 
-12.0 ± 0.4** 
  
 
n 8 
 
8 
1.1 Hz ramp 
train 
(P100) 
  
     
 Area (pC/nA) 0.33 ± 0.04 
 
1.82 ± 0.19** 
 n 8 
 
13 
  
     
        
 
  
    
Versus WT 
       *  =  P < 0.05 
       **  =  P < 0.005 
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Comparisons with other SCN5A mutations 
Two other mutations have been identified previously affecting the same residue as 
R225P, but the associated clinical phenotypes and functional disturbances are different. 
Mutation R225Q was identified in a heterozygous subject exhibiting a mild form of 
LQTS without reported features of cardiomyopathy [32]. We characterized NaV1.5-
R225Q. (Figure 20; Table 2) and found rather minor differences in channel activation and 
channel availability (hyperpolarized shifts) compared with WT channels. We also 
observed an increased persistent current (Table 2) although ramp currents did not differ 
with that of WT channels. Mutation R225W was identified in a heterozygous woman 
without symptoms, but also in her child with severe conduction disturbances who had a 
second mutation (W156X) inherited from the father [33]. Functional studies of the 
R225W mutation demonstrated a positively shifted channel availability curve and a 
significant decrease in current density, distinct from the constellation of findings we 
observed for R225P. 
By contrast, the functional properties of R225P channels resembled features of 
two other SCN5A mutations identified in subjects diagnosed with either dilated 
cardiomyopathy (R814W) [21], [23] or multifocal ventricular ectopy with reversible 
contractile dysfunction (R222Q) [24], [25]. Mutation R222Q affects another conserved 
arginine residue in the D1/S4 voltage sensor segment and is located approximately one 
helix turn away from position 225. The R814W mutation also alters a conserved voltage 
sensor arginine residue but in the second domain. We compared biophysical properties of 
R222Q and R814W and found that both mutations exhibit altered conductance-voltage 
relationships and predispose channels to activation at more hyperpolarized potentials 
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during slow voltage ramps similar to R225P (Figure 21; Figure 22). In contrast to R225P, 
neither R222Q nor R814W exhibited increased persistent sodium current (Table 2).  
A comparison of normalized ramp currents for these three mutants with that of a 
representative LQTS mutation (delKPQ) reveals an interesting segregation of the voltage 
range in which the currents peak (Figure 21; Table 2). Specifically, those mutations 
clinically associated with impaired ventricular function peak at more hyperpolarized 
potentials than the LQTS mutation. Additionally, average ramp currents exhibited by 
R225P are nearly bifid with one component peaking around -70 mV (similar to R222Q 
and R814W) while the second component peaks near -40 mV, closer to delKPQ. We 
suggest that the hyperpolarized activation of R222Q, R814W and the main component of 
R225P ramp currents correlate with the altered activation voltage dependence, whereas 
the more depolarized activation observed for delKPQ and the second component of 
R225P are associated with increased persistent sodium current and a slower time course 
of fast inactivation. Finally, both R814W [23] and R225P exhibit similar enhanced slow 
inactivation properties, but R222Q was not previously tested in this manner. 
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Figure 20. Biophysical properties of Na
V
1.5-R225Q.  (A) Representative traces of 
WT (top) and R225Q (bottom) sodium channels. (B) Current-density/voltage plots of 
WT and R225Q. (C) Voltage dependence of activation and channel availability for 
WT and R225Q. (D) Representative traces of WT and R225Q at -20 mV. (E) Voltage-
dependence of inactivation time constants (open symbols represent fast component; 
closed symbols represent slow component) for WT and R225Q. (F) Normalized TTX-
subtracted average ramp-currents (0.32 mV/ms) of WT and R225Q measured as a 
percentage of peak I
Na
 (-20 mV). All data are represented as mean ± S.E.M for n = 7 - 
15 cells. 
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Figure 21. Comparison of normalized ramp-currents. Normalized TTX-subtracted 
averaged ramp-currents from R225P and other NaV1.5 mutations associated with 
multifocal ventricular ectopy with impaired cardiac contractility (R222Q), sporadic 
dilated cardiomyopathy (R814W), and congenital long-QT syndrome (delKPQ). All 
data are represented as mean for n=7-15 cells. 
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Figure 22. Window-currents. (A) Overlay of Boltzmann-fitted conductance – 
voltage (filled symbols) and channel availability (open symbols) curves of WT and 
mutations R222Q, R814W, and delKPQ. (B) Panel A enhanced to emphasize window-
currents. All data are represented as mean ± S.E.M. for n = 7 - 12 cells. 
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Amiodarone effects on R225P 
Because the proband responded to treatment with amiodarone, we compared the 
pharmacological effects of this drug on WT and mutant channels (Figure 23; Figure 24; 
Table 4). For both WT and R225P, amiodarone (3 M) slowed activation kinetics (Figure 
24B), and significantly altered voltage-dependence of inactivation (Figure 23A) and 
recovery from inactivation (Figure 23C). Additionally, the drug had mutant-specific 
effects including suppression of persistent sodium current (Figure 24C; Table 4) and a 
hyperpolarized shift in the conductance-voltage relationship (Figure 23A) resulting in an 
accentuated window current. Interestingly, amiodarone did not alter the peak ramp 
current density, but caused a significant decrease in charge movement determined for 
R225P channels (Figure 23B). The effect of amiodarone to slow recovery from 
inactivation for both WT and R225P channels likely explains a profound reduction in 
channel availability during pulse trains (Figure 23D; Table 4) and a decrease in charge 
movement observed in repetitive ramp experiments (Figure 24D; Table 4). The 
suppression of channel availability most likely dominates the effects of amiodarone on 
NaV1.5 and may account for the suppression of ventricular ectopy in the proband. 
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Figure 23. Effects of amiodarone on NaV1.5-R225P.  (A) Activation and channel 
availability properties of WT and R225P in the presence of amiodarone (open 
symbols, dashed lines) or DMSO (filled circles, solid lines). All data were fit with a 
Boltzmann function. (B) TTX-subtracted averaged ramp-currents (0.32 mV/ms) of 
WT and R225P normalized to cell capacitance in the presence of amiodarone (dashed 
lines) or DMSO (solid lines). (C) Recovery from fast inactivation of WT and R225P in 
in the presence of amiodarone (open symbols, dashed lines) or DMSO (filled circles, 
solid lines). The data were fit with a double exponential curve. (D) Pulse trains (2Hz; -
20mV) with an activating pulse of 100ms of WT and R225P channels in the presence 
of amiodarone (open symbols, dashed lines) or DMSO (filled circles, solid lines). All 
data are represented as mean ± S.E.M for n=5-12 cells. 
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Figure 24. Effects of amiodarone on NaV1.5-R225P. (A) Current-density – voltage 
plots of WT and R225P channels in the presence of 0.01% DMSO (control, solid 
symbols) or amiodarone (open symbols). (B) Activation kinetics measured as time to 
peak current following an activation pulse to -20 mV (holding potential -120 mV). (C) 
Persistent current as a percentage of peak INa from WT and R225P in the presence of 
DMSO or amiodarone. WT persistent current non-determinable (N. D.) in the 
presence of amiodarone. (D) Charge movement in response to consecutive 500 ms 
ramp-current protocols (1.1 Hz; 100 pulses) in DMSO (closed symbols) and 
amiodarone (open symbols) for WT (black circles) and R225P blue (triangles). 
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Table 4. Effects of amiodarone on WT-NaV1.5 and R225P channels. 
 
       
Amiodarone 
(3µM) 
WT –  
DMSO 
WT - 
Amiodarone 
R225P - 
DMSO 
R225P - 
Amiodarone 
Activation 
V½ -40.4 ± 1.1 -41.4 ± 0.7 -34.5 ± 1.5* -41.0 ± 1.2 
k 6.7 ± 0.3 6.8 ± 0.2 11.1 ± 0.5** 10.7 ± 0.4** 
n 7 11 6 10 
  
  
  
  
Inactivation 
V½ -85.0 ± 0.8 -92.2 ± 1.8** -85.2 ± 1.1 -91.6 ± 1.9* 
k -6.2 ± 0.1 -10.1 ± 0.7** -6.8 ± 0.2* -10.8 ± 0.7** 
n 8 10 8 12 
     
  
Window-
currents 
Voltage -61.00 ± 0.03 -61.6 ± 0.7 -63.2 ± 1.8 -68.0 ± 1.3** 
Activity 0.034 ± 0.001 0.044 ± 0.002** 0.072 ± 0.004** 0.093 ± 0.003** 
n 5 7 7 9 
  
  
  
  
Recovery 
from 
inactivation 
A1 0.87 ± 0.01 0.19 ± 0.07** 0.88 ± 0.02 0.13 ± 0.03** 
1 8.0 ± 1.1 6.8 ± 2.7 10.3 ± 1.0 5.6 ± 1.4 
A2 0.13 ± 0.01 1.03 ± 0.06** 0.12 ± 0.02 1.04 ± 0.05** 
2 217 ± 36 2130 ± 434** 245 ± 39 1940 ± 293** 
n 7 8 8 8 
  
  
  
  
Persistent INa 
% peak 0.08 ± 0.02 -0.15 ± 1.16 0.43 ± 0.08** 0.17± 0.05 
n 5 8 8 7 
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Amiodarone  
(3µM) 
WT –  
DMSO 
WT - 
Amiodarone 
R225P - 
DMSO 
R225P - 
Amiodarone 
      
Time to 
peak  
(-20 mV) 
Peak (ms) 0.63 ± 0.02 0.93 ± 0.05** 0.92 ± 0.05* 1.04 ± 0.02* 
n 5 8 9 14 
  
  
  
  
500ms 
Ramps 
(Paired) 
mV -49.0 ± 3.6 -59.7 ± 1.7** -57.2 ± 2.5 -62.4 ± 1.0 
% peak -0.9 ± 0.1 -0.5 ± 0.1** -4.6 ± 0.5** -3.5 ± 0.5** 
Area (pC/nA) 1.2 ± 0.2 1.1 ± 0.3 5.8 ± 0.9** 2.8 ± 0.3** 
n 10 10 11 11 
  
  
  
  
Frequency 
dependent 
inhibition 
100ms 
1 Hz 
P1/P100 0.96± 0.04 0.30 ± 0.01** 0.86 ± 0.03** 0.18 ± 0.01** 
n 10 10 10 10 
     
2 Hz 
P1/P100 0.89 ± 0.03 0.25 ± 0.01** 0.69 ± 0.02** 0.10 ± 0.01** 
n 7 8 8 12 
  
 
    
1.1 Hz 
ramp train 
(P100) 
Area (pC/nA) 0.30 ± 0.5 0.02 ± 0.01* 1.12 ± 0.13** 0.04 ± 0.02** 
n 6 6 6 7 
  
  
  
Versus WT (DMSO) Versus R225P (DMSO) 
  
*  = P < 0.05 Bold  P < 0.05 
  
**  =  P < 0.005 Bold, Italices  P < 0.005 
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Discussion 
 
We present functional and pharmacological studies of a novel mutation in the 
principal cardiac voltage-gated sodium channel associated with multifocal ventricular 
ectopy with reversible ventricular dysfunction. Our data provide a biophysical profile of 
the mutant channel and examine pharmacological mechanisms responsible for the 
favorable clinical response to amiodarone. The novel mutation, R225P, adds to the 
growing structural and functional diversity of mutations in SCN5A responsible for 
inherited arrhythmia susceptibility and highlights the unique phenotype associated with 
mutations in first and second domain voltage sensors. 
 
Phenotypes associated with SCN5A voltage sensor mutations 
The mutation NaV1.5-R225P alters a critical arginine residue located in the 
voltage sensing S4 segment of the first domain (D1), one of the α-helical structures 
involved with detecting changes in membrane potential. Insertion of a proline is generally 
predicted to distort the secondary structure of an α helix. Despite this predicted change in 
a critical voltage-sensor domain, the R225P channel was functional. A similar surprising 
tolerance of proline substitution in a voltage-sensor segment was noted  in previous 
studies on a skeletal muscle sodium channel mutation, NaV1.4-R1448P [34].  
Three previously identified SCN5A mutations associated with cardiomyopathy 
also affect critical arginine residues within the D1/S4 (R219H, R222Q) or D2/S4 
(R814W) segments and are associated with complex clinical phenotypes featuring atrial 
and ventricular arrhythmias, and cardiomyopathy [22], [24]–[26], [28], [30]. By contrast, 
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missense mutations replacing S4 segment arginine residues in D4 cause congenital long-
QT syndrome without contractile dysfunction [35]–[37]. This intriguing genotype-
phenotype divergence may stem from differences in the contributions of the various 
voltage sensing segments and how mutations within each domain affect sodium channel 
gating [38]. Importantly, the two other mutations identified at position NaV1.5-R225 
(R225W, R225Q) are associated with different clinical phenotypes and, correspondingly, 
different functional disturbances.  
The association of arrhythmia and cardiomyopathy with voltage sensor mutations 
was originally reported in 2005 by Olson and colleagues. A de novo D2/S4 mutation 
(R814W) was identified in a young woman who had dilated cardiomyopathy combined 
with atrial flutter and nonsustained ventricular tachycardia [21]. Our laboratory later 
demonstrated that this mutation causes prominent defects in the kinetics and voltage 
dependence of activation that promoted aberrant activation during slow voltage ramps 
[23]. A similar functional defect was subsequently observed for the D1/S4 mutation 
R222Q, which had been identified independently by four groups. The phenotype 
associated with R222Q was described variably as peripartum dilated cardiomyopathy 
[26], [27], arrhythmic dilated cardiomyopathy [22], escape capture bigeminy and 
cardiomyopathy [28], reversible ventricular ectopy and dilated cardiomyopathy or 
multifocal ectopic Purkinje-related premature contractions [24]. Most of these reports 
emphasized the high burden of ectopic premature ventricular beats and impaired cardiac 
contractility with the variable presence of atrial tachyarrhythmias.  
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Pathophysiological implications 
Given that three of the D1/S4 and D2/S4 mutations have common patterns of 
dysfunction, most notable for altered activation voltage dependence, a shared 
pathophysiology would be logical to assume. One demonstrable consequence of altered 
activation is aberrant sodium conductance at hyperpolarized potentials during voltage 
ramps. This in vitro phenomenon suggests that mutant sodium channels could produce an 
aberrant inward current at near resting membrane potentials of cardiac myocytes. This 
would promote enhanced automaticity and may specifically trigger ventricular 
extrasystoles arising ectopically from Purkinje fibers as suggested by computer modeling 
studies [24], [25]. A high burden of ectopic beats may lead to heart failure that can be 
reversed by pharmacological suppression of sodium current as was noted in our case and 
previous reports of R222Q. However, this same functional defect could possibly induce 
contractile dysfunction through disordered calcium handling [10], improper pH 
regulation [8], or disrupted mitochondrial function [39], [40] that might not be reversible. 
Interestingly, another D1/S4 mutation (R219H) associated with dilated cardiomyopathy 
and ventricular arrhythmia causes a novel type of sodium channel dysfunction (proton 
leak current) that could also disrupt intracellular pH regulation in myocytes [30].  
Unlike the previously characterized NaV1.5 voltage sensor mutations discussed 
above, ramp-currents produced by R225P propagate in two distinct sets of peaks. The 
first peak can be attributed to the large, hyperpolarized window current of the mutant 
channel, as seen with R814W and R222Q, while the second peak is a result of the 
persistent current produced by R225P, similar to the LQTS mutation delKPQ [31]. This 
interesting characteristic has been previously discussed in relation to the neuronal sodium 
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channel NaV1.3 in which biphasic peaks were attributed to window- and persistent 
currents respectively [41]. Consistent with observations made with other SCN5A 
mutations associated with LQTS [31], R225P exhibits increased persistent current and 
this may explain the prolonged QTc observed in the proband.  
 
Mechanism of amiodarone response 
Because amiodarone was successful in suppressing ventricular ectopy and 
restoring normal contractile function, we sought to determine the pharmacological effects 
of this drug on the mutant sodium channel. We found that amiodarone significantly 
suppressed persistent current recorded from cells expressing R225P, induced a slightly 
hyperpolarized increase in window-current, and changed the overall morphology of the 
ramp-current resulting in a decreased charge movement for the mutant channel. In 
addition, amiodarone also had a profound impact on recovery from inactivation that 
suggested a mechanism for dampening the deleterious biophysical dysfunction of R225P. 
Specifically, by prolonging recovery time from fast inactivation, amiodarone effectively 
diminished the pool of available mutant channels. Further, frequency-dependent block of 
channels in the presence of amiodarone was greater for R225P than WT channels. 
Because R225P is more sensitive to inactivation induced inhibition, we predict that 
amiodarone administration results in a global decrease in the total number of channels 
available to be activated, however, the proportion of WT channels in the population is 
enriched compared to R225P.  
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Conclusions 
We identified a novel de novo SCN5A mutation in a child with an amiodarone-
responsive multifocal ventricular ectopy-associated cardiomyopathy and elucidated the 
molecular mechanism responsible for the disorder. The mutation, R225P, affects a 
voltage sensor domain and causes a hyperpolarized shift in the voltage dependence of 
activation. Additionally, this mutation evokes increased persistent sodium current, a 
recognized biophysical defect underlying type 3 LQTS, and other biophysical 
abnormalities including enhanced slow inactivation. Amiodarone suppresses channel 
availability to a greater extent for the mutant and attenuates the aberrant ramp current, 
two plausible explanations for its therapeutic success in this case. The unique functional 
consequences of SCN5A voltage sensor mutations in D1 and D2 help explain the 
pathogenesis of an arrhythmia-associated cardiomyopathy that can be reversed with 
certain sodium channel blocking drugs.  
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CHAPTER III 
 
ELUCIDATING THE IMPACT OF NAV1.5 MUTATIONS ON CA
2+
 HANDLING 
IN ISOLATED VENTRICULAR CARDIOMYOCYTES 
 
Introduction 
Mutations in the human heart Na channel NaV1.5 have been associated with a 
range of disorders affecting cardiac rhythm. More recently, a subset of NaV1.5 mutations 
have also been associated with a form of heart failure [23]–[25]. This unexpected 
association creates an expanded clinical spectrum of conditions associated with cardiac 
sodium channelopathies and establishes a need to elucidate the relationship between 
cardiac Na channel dysfunction and cardiomyopathies.  
Intracellular ion homeostasis in myocytes is tightly regulated by multiple 
exchangers and transporters including the Na/Ca exchanger (NCX) and the Na/H 
exchanger (NHE) [8]. Through the NCX and the NHE, Na
+
 is directly coupled to Ca
2+
 
and pH levels within the cell such that an abnormally high intracellular [Na
+
] might affect 
Ca
2+ 
and H
+
 handling. Therefore, any change of intracellular Na
+
 levels due to cardiac 
sodium channel dysfunction might influence homeostasis of other intracellular ions. 
Some of the NaV1.5 mutations identified in heart failure patients (R222Q, R225P, and 
R814W) are predicted to cause an inappropriate influx of Na
+
 during diastole. Diastolic 
Na
+
 influx has the potential of disturbing Na
+
 and Ca
2+
 homeostasis that in turn could 
lead to myocardial damage. We hypothesized that certain cardiac sodium channel 
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mutations such as R222Q, R225P, and R814W may disturb intracellular Ca
2+
 and H
+
 
dynamics, indirectly leading to myocardial failure. 
The objective of this project is to establish a mechanistic relationship between Na 
channel dysfunction and impaired contraction as a consequence of altered ion and/or pH 
homeostasis in cardiac myocytes. We tested this by expressing WT or mutant cardiac 
sodium channels in rabbit cardiomyocytes using lentiviral vector.  We then analyzed and 
compared the effects of these channels on intracellular Ca
2+
 measurements, with future 
experiments planned to analyze pH regulation. We expected to see alterations in 
intracellular Ca
2+
 and H
+
 levels compared to myocytes expressing wild-type NaV1.5.  
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Materials and Methods 
 
Cloning of NaV1.5 and mutant cardiac sodium channels 
A cDNA encoding human NaV1.5 was cloned into the first position of the 
bicistronic vector pRc-CMV_IRES2_ with a marker gene (dsRed; eGFP; CD8) under the 
control of the IRES2 element. Positively transfected cells were identified by their 
fluorescent emission or the binding of beads conjugated with anti-CD8 antibodies. 
Mutations were created in the pRc-CMV-NaV1.5-IRES2-(marker) plasmid using site-
directed PCR mutagenesis. Disease-related cardiac sodium channel mutations created for 
use in this set of experiments were: NaV1.5-R222Q, NaV1.5-R814W, and NaV1.5-
delKPQ. In some experiments, the mutation F1760A was designed and introduced into 
NaV1.5 and mutants to create a lidocaine-resistant mutation. In order to test function of 
all plasmids, human-derived tsA201 cells (HEK293 cell line expressing SV40 large T 
antigen) were transiently co-transfected with 1.0 µg of WT or mutant NaV1.5 plasmid and 
the β1 subunit using FuGeneHD (Roche Diagnostics, Indianapolis, IN). Biophysical 
characterization was performed as described in Chapter II to validate channel properties. 
 
Adenoviral vector production 
Adenovator 
Adenovirus was produced using the AdenoVator system (QBiogene; now MP 
Biomedicals, Santa Ana, California, USA) as instructed within the manual (Figure 25). 
Briefly, the gene of interest was cloned into the multiple cloning site of the transfer 
vector supplied in the kit using restriction enzyme digests and ligations. The completed 
71 
 
transfer vector was then linearized with the restriction enzyme PmeI and co-transformed 
into electrocompetent bacterial cells, BJ5183, using an Ecoli Pulser Transformation 
Apparatus (Bio-Rad, Hercules, California, USA). Recombinant plasmid DNA was 
selected for on agar plates containing Kanamycin. AdenoVator (pAd) plasmids 
containing the adenoviral backbone and gene of interest were identified by screening the 
recombinants for plasmid size and banding pattern through restriction enzyme analysis. 
Positive pAd clones were then amplified in DH5α bacteria to produce transfection quality 
DNA.  
The vector plasmid pAd was then linearized with the enzyme PacI and transferred 
into QBI-293A cells containing complementary adenoviral proteins necessary to create 
functional adenovirus by electroporation (ECM 830 Square Wave Electroporation 
System; BTX, Harvard Apparatus, Holliston, Massachusetts, USA) or FuGene6. 
Transfected cells were then overlaid with agarose for viral plaque production. After 15-
20 days, plugs were removed from the agarose above visible plaques and added to fresh 
media then applied to QBI-293A (Qbiogene) cells in a 10cm dish for small scale virus 
amplification. This virus was collected after 5-7 days and tested on tsA201 cells for 
function by fluorescence. Functional adenoviral vectors were then amplified in 15cm 
plates and collected after 15 days, concentrated using spin columns, and frozen in single 
use aliquots for future experiments. 
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Figure 25. Recombinant adenovirus production by AdenoVator. Flowchart 
describing the process of adenoviral vector creation and production using the 
AdenoVator method from QBiogene. Image adapted from the AdenoVator product 
applications manual (Version 1.1) (QBiogene, Carlsbad, California, USA). 
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RAPAd 
A second method for creating functional adenovirus (RAPAd) was acquired from 
the Gene Transfer Vector Core of the University of Iowa (Courtesy of Beverly L. 
Davidson, Ph.D. and Maria L. Scheel) (Figure 26) [42]. In brief, the RAPAd adenoviral 
system uses a two plasmid method for adenoviral vector creation. The gene of interest is 
cloned into the multiple cloning site of the pacAD5-K-NpA shuttle vector. Both the 
shuttle vector and the backbone plasmid, pacAd5 9.2-100, are digested with PacI then 
transfected together into QBI-293A cells with FuGene6 for viral production. Plaque 
formation generally occurred 10-14 days after transfection. After plaques began to form, 
the crude viral lysate was harvested by collecting all the cells and media from the dish 
and subjecting the lysate to three freeze/thaw cycles in a dry ice/EtOH bath and a 37°C 
water bath. Cell debris was then pelleted by centrifugation and the lysate was collected 
and stored at -80°C or used immediately for amplification. Virus was amplified by 
adding a proportion of viral lysate to 293A cells cultured in T150 cell culture flasks. 
After cells demonstrated cytopathic effects (CPEs), the cells and media were gently 
collected and cells were pelleted by centrifugation and cell media was removed. The cells 
were resuspended in 10mM Tris, pH 8.0, 100 mM NaCl (0.5mL – 1.0mL per flask) and 
subjected to three freeze/thaw cycles with subsequent centrifugation to pellet the cell 
debris. The viral supernatant was then collected and frozen at -80°C as the viral stock in 
single use aliquots. 
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Figure 26. Recombinant adenoviral vector production using the RAPAd 
adenoviral expression system. Minimal steps are necessary to produce adenoviral 
vectors using the RAPAd approach. This image used courtesy of the Gene Transfer 
Vector Core at the University of Iowa. 
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Production of recombinant lentivirus 
Lentivirus carrying the desired gene was produced by transient transfection of 
three plasmids (gift from Dr. Josh Bauer, Vanderbilt University, Nashville, Tennessee, 
USA) into a packaging cell line (HEK-293FT).  WT or mutant channel cDNA was cloned 
into the FG12-CMV plasmid containing one of three expression markers, hUBC-GFP, 
IRES2-dsRed.MST, or IRES2-CD8. FuGeneHD was used to co-transfect the FG12 
vector plasmid, packaging plasmid psPax2, and the envelope plasmid pMD2.G 
containing the ‘G’ glycoproteins of the vesicular stomatitis virus (VSV-G), important for 
increased tropism [43], at a ratio of 16:9:5.  Over expression of VSV-G is toxic and a 
larger proportion of pMD2.G resulted in cell death and inefficient viral production.  
After 24 hours, media was changed and supplemented with 4mM caffeine and 
10mM Na-butyrate.  Three days post-transfection, supernatant was collected and filtered 
through a 45 micron filter then concentrated using Amicon Ultra-15 centrifugal filters 
(EMD Millipore, Billerica, Massachusetts, USA).  Concentrated virus was collected and 
stored in single-use aliquots at -80°C.   
Isolated guinea pig or rabbit ventricular cardiomyocytes were infected with 
lentivirus containing either WT or mutant channel cDNA.  Polybrene (Hexadimethrine 
bromide; Sigma-Aldrich, St. Louis, Missouri, USA) (8ug/mL) was supplemented at time 
of infection to increase cell susceptibility to the lentivirus.  One day post-infection, the 
media was changed to avoid polybrene toxicity.  Experiments were performed 48 – 72 
hours post-infection to allow for adequate expression of transduced gene. Dr. Peter 
Mohler (Ohio State University, Columbus, Ohio, USA) provided helpful guidance with 
lentiviral production. 
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Neonatal rat ventricular myocytes  
Neonatal rat ventricular myocytes (NRVMs) were supplied as a gift from the lab 
of Dr. Chee Lim (Isolations by Manuel Chiusa, Ph.D.; Vanderbilt University) and 
isolated as previously described [44], [45]. Briefly, hearts were removed and collected 
from several neonatal rat pups and placed in ice cold HBSS (Hank’s Balanced Salt 
Solution; Life Technologies, Grand Island, New York, USA). Ventricles were removed 
from whole hearts and transferred to a fresh dish of HBSS where each ventricle was cut 
into 3 – 4 pieces. Ventricular tissue was then transferred into containers containing 
trypsin solution (15 mg trypsin (Gibco; Life Technologies), 25 mL HBSS; filtered and 
kept on ice) and shaken overnight in a cold room (approximately 18 hours). The next day, 
the trypsin was aspirated and washed with media containing DMEM (Dulbecco’s 
Modified Eagles Medium; Life Technologies), 7% Fetal Bovine Serum (FBS; Gibco). 
The media was aspirated and replaced with collagenase solution (50mg Worthington 
collagenase type II (Worthington Biochemical Corporation, Lakewood, New Jersey, 
USA), 50 mL HBSS) and the tissue and collagenase were shaken at 40°C until myocytes 
broke free from tissue and the media became cloudy. The supernatant was collected and 
stored on ice and collagenase solution was added back to the tissue. The collagenase 
collection was repeated 4 more times. Myocytes were collected from the combined 
supernatants by centrifugation and washed with 7% FBS/DMEM, spun again, then finally 
brought up in 7% FBS/DMEM. Cells were initially plated for 45-60 minutes to allow 
fibroblasts to settle. Supernatant containing an enriched ventricular myocyte population 
was then collected and plated as needed for experiments and cultured at 37°C and 5% 
CO2. 
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Guinea pig cardiomyocyte isolation 
This protocol for isolation of guinea pig cardiomyocytes was modified from the 
lab of Robert Harvey, Ph.D. [46] (University of Nevada School of Medicine, Reno, 
Nevada, USA) and approved by the IACUC of Vanderbilt University. All solutions used 
during the isolation were bubbled with 100% O2 and warmed in a water bath to maintain 
37°C when applied to the heart. Male, adult Hartley guinea pigs (250-350g) were 
purchased from Charles River (Wilmington, Massachusetts, USA). The guinea pig was 
given an intraperitoneal injection of heparin (500 units) five minutes prior to 
administration of pentobarbital (100mg/kg). After the animal no longer responded to 
stimuli, the chest was shaved and doused with ethanol. The chest cavity was opened and 
the heart was excised. The aorta was cannulated and the heart was attached to a pump-
driven Langendorff apparatus.  
The heart was then perfused with a physiological saline solution (PSS) plus 
calcium (in mM: 140 NaCl, 5.4 KCl, 2.5, MgCl2, 11 glucose, 5.5 HEPES, 1.5 CaCl2; pH 
7.4 at 37°C). After five minutes, the perfusion solution was changed to Ca-free PSS to 
suppress mechanical activity and allowed to flow through the heart for five minutes. 
Collagenase (Worthington Class II) was added to Ca-free PSS (0.4 mg/ml) and perfused 
through the heart for ten minutes. After eight minutes of collagenase perfusion, the heart 
was removed from the Langendorff setup and placed in KB solution (Krebs-Henseleit 
Buffer; in mM: 110 potassium glutamate, 10 KH2PO4, 25 KCl, 2 MgSO4, 20 taurine, 5 
creatine, 0.5 EGTA, 20 glucose and 5 HEPES; pH 7.4 at 37°C). Vessels and fat were 
trimmed away from the heart muscle, then ventricles were collected and separated from 
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the atria. Ventricular tissue was cut into small pieces and placed in warmed KB solution 
then finely minced and triturated with a wide-mouth sterile transfer pipette in order to 
release individual cells from the tissue. The slurry was then filtered through a 300 µm 
filter and the myocytes were pelleted by centrifugation (20xg for 5 minutes). The 
supernatant was aspirated and replaced with fresh KB solution and allowed to recover for 
30 minutes before plating in culture media. The media contained Mimimum Essential 
Medium (MEM) containing Hanks salts and L-glutamine (Gibco-Invitrogen 11575-032) 
supplemented with streptomycin (100 μg/ml), penicillin (100 units/ml), bovine serum 
albumin 1 mg/ml, Insulin-Transferrin-Selenium-X Supplement (Gibco-Invitrogen 51500-
056) (1X). Isolated ventricular myocytes recovered in a 37°C incubator (5% CO2) for 2 
hours before being infected with virus. Cells typically remained viable for 72 – 96 hours. 
 
Rabbit ventricular cardiomycoyte isolation 
Isolated rabbit ventricular myocytes were acquired from Courtney Campbell, 
Ph.D. and Rick Welch (George lab). Cardiomyocytes were isolated as previously 
described [47]. Briefly, New Zealand White rabbits (6-7 lbs; Charles River Canada) were 
sedated with intramuscular acepromazine then anesthetized with intravenous 
pentobarbital sodium. Hearts were quickly excised and arrested on ice for 5 minutes in 
nominally calcium-free minimum essential medium solution (MEM, Joklik 
modification). Hearts were hung on a Langendorff apparatus and perfused at 37°C for 10-
15 minutes in the same MEM solution gassed with 95% O2 and 5% CO2. The perfusion 
was then switched to MEM solution containing 0.05 mg/ml Liberase TH (Roche Applied 
Sciences, Indianapolis, Indiana, USA). After 5 minutes, serial tissue samples were 
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collected in order to determine the progression of tissue digestion. When the majority of 
ventricular myocytes released were quiescent and rod-shaped (7-20 minutes), the 
ventricles were removed from the heart and placed in MEM solution containing 1% 
bovine serum albumin (BSA). The tissue was minced, gently triturated with a wide-
mouthed sterile transfer pipette, and filtered through a 100 µm cell strainer (BD 
Biosciences, San Jose, California, USA) into a 50 ml conical tube. The myocytes were 
allowed to settle by gravity at room temperature until a soft pellet was formed (30 – 45 
minutes). The supernatant was aspirated and ventricular myocytes were resuspended in 
MEM with BSA. Myocytes were plated and incubated at 37°C with 5% CO2. The 
experimental procedure for isolating rabbit cardiac myocytes was approved by Vanderbilt 
University IACUC. 
 
Calcium imaging of isolated cardiomyocytes 
Isolated rabbit or guinea pig ventricular cardiomyocytes were collected from 
culture conditions by gentle centrifugation (20xg; 5 minutes).  The supernatant was 
removed and cells were resuspended in Tyrode’s solution (TS) then loaded with the 
ratiometric calcium-sensitive dye, Fura-2 AM (2µM), for 20 minutes.  The composition 
of TS for Fura-2 loading was (in mM): 145 NaCl, 5.4 KCl, 1.2 CaCl2, 0.3 NaH2PO4, 0.5 
MgCl2, 5.5 glucose, and 5 HEPES, pH adjusted to 7.4 with NaOH. After dye loading, the 
cardiomyocytes were centrifuged, washed with TS to remove excess extracellular Fura-2, 
and then suspended in TS with 2 mM Ca
2+
 for 30 min to ensure complete hydrolysis of 
the intracellular ester. 
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Fura-2 signals were recorded on an IonOptix calcium-imaging station (Ionoptix, 
Milton, Massachusetts, USA).  Briefly, Fura-2 loaded myocytes were placed in the 
recording chamber and field-stimulated (5ms; 15V) to induce cardiomyocyte contractions 
at 0.5 Hz or 1 Hz.  Calcium transients were recorded by alternating excitation of the Fura-
2 dye from 340nm to 380nm (250 Hz) and recording the fluorescent emission at 510nm.  
Background fluorescence was subtracted from all recordings. The ratio of emission 
(F340/F380) is indicative of the calcium transient in the individual myocyte.  Data 
acquisition and offline analysis were performed using IonWizard 6.2 software (IonOptix). 
 
Electrophysiology 
Biophysical characterization of sodium channels from viral-vector transduced 
tsA201 cells were recorded and analyzed as described in Chapter II. Sodium currents 
from isolated ventricular myocytes were recorded at room temperature (22-23°C) using 
the whole-cell patch clamp technique. Electrodes were pulled from thin-wall borosilicate 
glass (OD: 1.2 mm, Warner Instrument Corp., Hamden, Connecticut, USA) on a P-97 
multistage Flaming-Brown micropipette puller (Sutter Instruments, Novato, California, 
USA) and fire polished to a resistance between 0.8 and 1.2 MΩ. Data acquisition began 
10 minutes after whole-cell configuration was established. Throughout the entirety of the 
experiment, a gravity-driven perfusion system (Perfusion Pencil system; AutoMate 
Scientific, Berkeley, California, USA) was used to superfuse positively transfected 
tsA201 cells with bath solution containing (in mM): 10 NaCl, 5 CsCl2, 125 TEA-Cl, 1.8 
CaCl2, 1 MgCl2, 10 HEPES; and 10 glucose, pH 7.4 (adjusted with CsOH). The pipette 
solution (intracellular solution) contained (in mM): 5 NaCl, 150 CsF, 5 EGTA, and 10 
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HEPES, pH 7.2 (adjusted with CsOH). Series resistance was compensated at 90%. Leak 
currents were subtracted by using an online P/4 procedure. Cells with voltage error 
greater than ±3 mV were excluded from analysis. Data acquisition was carried out using 
an Axopatch 200B patch clamp amplifier and pCLAMP 10.0 software (Molecular 
Devices, Sunnyvale, CA). All data were analyzed using pCLAMP 10.0 or Microsoft 
Excel 2007 and plotted using SigmaPlot 10.0 (Systat Software, Inc., San Jose, CA). 
Statistical analysis was performed using Student’s t-Test. 
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Results 
 
Animal model and culture 
For this project, we chose to use adult guinea pig and rabbit cardiomyocytes 
because of their similarities to human ventricular action potentials compared to those of 
rats or mice (Figure 27). We optimized isolation protocols for both animals that yielded 
quiescent, rod-shaped, calcium-sensitive cardiomyocytes for experimentation. Proper 
myocyte function was verified through patch clamp and calcium imaging experiments 
(Figure 28). Because of the overall size of the cardiomyocyte, sodium current recordings 
in the native myocyte were very large, therefore, we decreased extracellular [Na
+
] in 
order to control INa and maintain minimal voltage error. 
Calcium imaging of isolated ventricular cardiomyocytes was performed using the 
ratiometric dye, Fura-2 AM. To elicit a calcium transient, myocytes were field stimulated 
at varying frequencies to determine the native calcium transient induced by excitation-
contraction coupling (Figure 28C) Viable cells were capable of being stimulated to 
produce action potentials or calcium signals.  
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A 
B 
Figure 27. Action potential morphologies. (A) A representiation of the human 
cardiac action potential and the multiple currents responsible for the overall shape 
[64]. (B) Comparitive recordings of action potentials from animals commonly used 
for cardiac research [65]. 
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Figure 28. Properties of the isolated rabbit ventricular myocyte. A 
representative sodium current family (A) and a stimulated action potential (B), 
recorded from individual isolated rabbit ventricular myocytes. (C) Stimulated Fura-
2 signal (ratio of F340/F380; background subtracted) recorded from an individual 
myocytes (black line) overlaid with concordant measurement of sarcomere length 
(red) showing myocyte contraction. Data extrapolated using IonWizard software 
and Microsoft Excel. 
20 mV
50 ms
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10 ms
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Lidocaine – resistant NaV1.5 
Our goal for this project was to express mutant cardiac sodium channels in native 
cells in order to determine adverse consequences of NaV1.5 mutations R222Q, R814W, 
and delKPQ. Because the cardiac sodium channel, NaV1.5, is abundantly expressed in 
native cardiomyocytes, it was desirable to use a pharmacological ‘tag’ to isolate 
exogenously-expressed channels. For this purpose, we engineered the mutation NaV1.5-
F1760A, which confers lidocaine-resistance upon the channel (Figure 29A).  
At a concentration of 100 µM lidocaine, tonic block of wild type current is near 
70% while the F1760A mutation is more resistant to drug and is only reduced by 30%. 
Similar results were seen in the background of mutation R814W (R814W: 73% tonic 
block; R814W-F1760A: 24% tonic block) (Figure 29B). Lidocaine also blocks the 
cardiac sodium channel in a use-dependent manner, resulting in a loss of about 30% of 
current for both wild type and R814W channels after 100 pulses (1 Hz). The F1760A 
mutation abolished the use-dependent effect of lidocaine for both WT and mutant 
channels (Figure 29C). 
In both the WT and R814W – lidocaine-resistant mutants, the voltage dependence 
of activation was slightly hyperpolarized while the channel availability was right-shifted 
with a less-shallow slope. Because these changes affected both WT and R814W in a 
similar pattern, this resulted in a similar, slightly hyperpolarized shift in the window-
current for both channels. The relationship between WT and R814W remained the same, 
with R814W presenting a larger, hyperpolarized window-current (Figure 30A). 
Analysis of slow ramp currents (2s; 80mV/s) produced by F1760A and R814W-
F1760A revealed that the F1760A mutation alone introduced a large, broad ramp current 
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into the WT channel and exaggerated the ramp current of R814W to very large peak 
values (Figure 30B). Because the F1760A mutation confers similar characteristics into 
the WT mutation as those that we suspect are responsible for the heart failure phenotype 
in R222Q and R814W, we chose not to continue with the lidocaine-resistant, F1760A 
channels. 
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Figure 29. Lidocaine-resistance of NaV1.5-F1760A. (A) Model of NaV1.5 with 
the approximate location of the F1760A mutation marked (black circle). (B) Tonic 
block achieved by lidocaine on WT, R814W, and the lidocaine-resistant variants 
(F1760A, R814W-F1760A). (C) Pulse-train experiments (-20 mV; 1 Hz; 100 
pulses) in the absence or presence of lidocaine. Normalized, 100
th
 pulses are 
shown. Lidocaine concentration was 100 µM for all experiments. All data are 
represented as mean ± S.E.M for n = 5 – 7 cells. 
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Figure 30. Properties of NaV1.5-F1760A. (A) Overlay of Boltzman-fitted 
activation curves with Boltzmann-fitted channel availability properties. Window 
current can be seen as the area under where the curves intersect for each respectable 
channel. (B) Ramp-currents elicited by a two-second ramp current protocol from -
120 mV to 40 mV (80mV/s). All data are represented as mean ± S.E.M for n = 11 – 
15 cells. 
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Adenoviral vector production 
Recombinant adenovirus produced using the AdenoVator system was capable of 
transducing guinea pig, rabbit, and neonatal rat ventricular myocytes, as demonstrated by 
fluorescence 48 hours post-infection. Multiple attempts were made to create adenoviral 
vectors containing WT or mutant cardiac sodium channels in the AdenoVator system; 
however, we were not successful as plaques did not form in cells transfected with the full 
adenoviral DNA containing SCN5A and variants. 
We then contracted with the University of Iowa Gene Transfer Vector Core 
(GTVC) in order to produce adenoviral vectors containing WT or mutant cardiac sodium 
channels using the RAPAd method [42]. The GTVC kindly provided our lab with shuttle 
and backbone vectors necessary for virus production and, in concert, our lab and the 
GTVC attempted to produce adenoviral vectors. 
We were capable of producing control adenovirus containing the gene encoding 
the marker mCherry that was able to transduce both guinea pig and rabbit ventricular 
cardiomyocytes, characterized by fluorescence emission at appropriate wave lengths. 
However, the RAPAd system was also unable to produce adenoviral vectors containing 
NaV1.5 or the alternative channel mutations. This problem was mirrored at the GTVC, as 
they were also unable to produce the appropriate virus after multiple attempts, possibly 
due to insert size or overexpression of the gene of interest (personal communication with 
GTVC). 
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Lentiviral vectors containing NaV1.5 
Control and channel lentiviral vectors were successfully created, tested, and 
verified for function by infection of tsA201 cells (Figure 31). Attempts to infect isolated 
ventricular cardiomyocytes of both guinea pig and rabbit with lentivirus carrying CMV-
SCN5A-IRES2-dsRed.MST were unsuccessful. Multiple infections with varying viral 
doses, infection times, and recovery times for expression (48-96 hours post infection) 
were examined without success. However, lentiviral vectors containing WT or mutant 
channel genes followed by the CD8 marker (CMV-SCN5A*-IRES2-Leu2(CD8)) were 
capable of transducing NRVM, guinea pig, and rabbit isolated ventricular myocytes, 
verified by CD8 antibody conjugated bead attachment 48 – 72 hours post infection 
(Figure 32).  
Calcium imaging by Fura-2 signal was performed on transduced rabbit ventricular 
myocytes to identify any changes of the calcium transient as a result of exogenous 
expression of the mutant cardiac sodium channels compared to WT channels (Figure 33-
Figure 39). We expected to see an increase in baseline calcium levels, shorter time to 
peak, an increased peak calcium transient, and a slower, drawn out recovery of the 
calcium transient reported by the Fura-2 ratio. Of the parameters tested, only the recovery 
of the Fura-2 signal (time to 90% baseline; 1 Hz) for R814W was significantly different 
(p < 0.05) compared to myocytes transduced with WT channels (Figure 39). Overall, 
though, transduction of isolated rabbit ventricular myocytes with WT or mutant channels 
resulted in mostly no significant differences. 
To examine the amount of channel expression we were achieving by lentiviral 
infection, we performed whole-cell patch clamp experiments on transduced 
91 
 
cardiomyocytes, examining current-density measurements of myocytes over-expressing 
WT or mutant cardiac sodium channel. Interestingly, in cells transduced with the 
lentiviral vectors, current-density did not increase, but rather decreased, contrary to what 
we had expected (Figure 40).  
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Figure 31. Lentiviral transduction of tsA201 cells. (A) Image verification of 
positive transduction of tsA201 cells with lentiviral vectors containing the sodium 
channel gene SCN5A and various marker proteins. (B) Current-density – Voltage 
plots of positively transduced tsA201 cells expressing the cardiac sodium channel 
NaV1.5. All data are represented as mean ± S.E.M for n = 6 - 8 cells. 
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Figure 32. Lentiviral transduction of cardiomyocytes. Neonatal rat ventricular 
myocytes and Adult Rabbit ventricular myocyte transduced with lentivirus 
containing the expression construct CMV-NaV1.5-IRES2-CD8. Black circles are 
CD8 antibody conjugated beads attached to the cardiomyocyte. 
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Figure 33. Baseline measurements of rabbit ventricular myocytes. (Top panels) 
Baseline sarcomere length measured in isolated myocytes during stimulation of 0.5 
or 1.0 Hz. (Bottom panels) Baseline Fura ratio in cardiomyocytes loaded with Fura-
2 during stimulation of 0.5 or 1.0 Hz. All data are represented as mean ± S.E.M. 
Number of cells measured (n) are listed along bottom of figures. 
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Figure 34. Departure velocity measurements of rabbit ventricular myocytes. 
Departure velocity measurements examine the rate of change of the respectable 
signal. (Top panels) Departure velocity of sarcomere length after stimulation at 0.5 
or 1 Hz, indicating rate of contraction. (Bottom panels) Departure velocity of the 
Fura ratio after stimulation at 0.5 or 1 Hz in cardiomyocytes loaded with Fura-2 
AM. All data are represented as mean ± S.E.M. Number of cells measured (n) are 
listed along bottom of figures.  
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Figure 35. Time to peak measurements of rabbit ventricular myocytes. (Top 
panels) Time to peak (90%) measurements of sarcomere length during stimulation 
at 0.5 or 1 Hz. (Bottom panels) Time to peak (90%) of the Fura ratio during 
stimulation at 0.5 or 1 Hz in cardiomyocytes loaded with Fura-2 AM. All data are 
represented as mean ± S.E.M. Number of cells measured (n) are listed along bottom 
of figures. 
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Figure 36. Measurement of peak height of rabbit ventricular myocytes. Peak 
height was measured as a percentage of baseline in order to account for differences 
in baseline measurements. (Top panels) Peak height in relation to baseline 
measurements of sarcomere length during stimulation at 0.5 or 1 Hz. (Bottom 
panels) Peak height of the Fura ratio during stimulation at 0.5 or 1 Hz in 
cardiomyocytes loaded with Fura-2 AM. All data are represented as mean ± S.E.M. 
Number of cells measured (n) are listed along bottom of figures. 
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Figure 37. Measurement of rate of recovery of rabbit ventricular myocytes 
after stimulation. Return velocity measurements indicate the rate at which the 
respective peaks return to baseline. (Top panels) Return velocity of sarcomere 
length during stimulation at 0.5 or 1 Hz. (Bottom panels) Return velocity of the 
Fura ratio during stimulation at 0.5 or 1 Hz in cardiomyocytes loaded with Fura-2 
AM. All data are represented as mean ± S.E.M. Number of cells measured (n) are 
listed along bottom of figures. 
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Figure 38. Time course of recovery of rabbit ventricular myocytes after 
stimulation. (Top panels) The time it takes to recover 50% of contracted sarcomere 
in relation to baseline during stimulation at 0.5 or 1 Hz. (Bottom panels) The time 
needed to recover 50% of peak Fura signal in relation to baseline during 
stimulation at 0.5 or 1 Hz in cardiomyocytes loaded with Fura-2 AM. All data are 
represented as mean ± S.E.M. Number of cells measured (n) are listed along bottom 
of figures. 
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Figure 39. Time course of recovery of rabbit ventricular myocytes after 
stimulation. (Top panels) The time it takes to recover 90% of contracted sarcomere 
in relation to baseline during stimulation at 0.5 or 1 Hz. (Bottom panels) The time 
needed to recover 90% of peak Fura signal in relation to baseline during 
stimulation at 0.5 or 1 Hz in cardiomyocytes loaded with Fura-2 AM. All data are 
represented as mean ± S.E.M. Number of cells measured (n) are listed along bottom 
of figures. 
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Figure 40. INa recorded from isolated rabbit ventricular myocytes. Sodium 
currents measured from native (black) myocytes or myocytes transduced with 
control lentivirus (blue) or lentivirus containing SCN5A (red). All data are 
represented as mean ± S.E.M. for n= 7 - 9 cells. * = p<0.05 compared to native 
sodium current density. 
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Discussion 
Cardiac sodium channel mutations associated with heart failure expand the 
clinical spectrum of disease states associated with the protein NaV1.5. Because of this 
unexpected correlation, we wanted to understand the mechanism of disease for the 
R222Q, R814W, and R225P mutations. We hypothesized that these mutations in the 
voltage sensing regions of their respective domains would result in an aberrant influx of 
sodium near membrane potentials typically associated with diastole, as identified by ramp 
current experiments. Proper myocyte function and cellular homeostasis relies on 
regulation of the sodium concentration gradient. Because of the direct relationship 
between sodium and calcium through the NCX, in this set of experiments, it was our aim 
to determine if the aberrant influx of sodium at hyperpolarized potentials produced by the 
mutations R222Q and R814W would disrupt calcium handling and potentially lead to 
myocardial insult. For sake of comparison, we chose to also characterize the LQTS 
mutation, delKPQ, which exhibits a larger ramp current then WT, however, peaks near 
the same membrane potential and should potentially result in a different calcium handling 
pattern, compared to R222Q and R814W. To test this, we chose to exogenously express 
WT or mutant cardiac sodium channels in guinea pig and rabbit isolated ventricular 
cardiomyocytes.  
 
Transduction of isolated ventricular cardiomyocytes  
Adenoviral vectors 
Expression of exogenous genes and proteins in primary cells is a difficult task. 
Because cardiomyocytes are fully differentiated, gene transcription and translation is 
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decreased to a minimum, usually reserved for maintenance and house keeper gene 
regulation. Adenovirus and adenoviral vectors drive expression of their genomic payload 
as an extra chromosome and they do not rely upon insertion of genetic material into the 
host genome, compared to lentivirus. Thus, our initial efforts were placed on creating 
adenoviral vectors containing the human cardiac sodium channel gene, SCN5A.   
We successfully produced control adenovirus capable of transducing guinea pig 
and rabbit cardiomyocytes with various marker proteins. Multiple attempts were made to 
produce adenovirus carrying the cardiac sodium channel gene and, ultimately, neither we 
nor the GTVC could create the necessary adenoviral constructs to transduce 
cardiomyocytes with human WT or mutant cardiac sodium channels.  
We are unable to identify a direct reason for both the AdenoVator and RAPAd 
processes to be unsuccessful. Both methods used to create adenovirus are capable of 
accepting a genetic payload of ~8 kb. The promoter, gene, and marker construct (CMV-
SCN5A-IRES2-mCherry) was roughly 8.5 kb, therefore, it is possible that our insert was 
excessive in length. However, attempts to create an adenoviral vector containing only 
promoter and channel (~6.5kb) were also unsuccessful in both vector producing systems. 
Another concern is overexpression of our gene of interest in the HEK-293A 
adenoviral production line. Adenoviral plasmid DNA is directly transfected into the HEK 
cell line, where transcription and translation machinery have immediate access to the 
expression construct. Expression of NaV1.5 driven by the CMV promoter over the time 
needed for viral production (10-14 days) could be excessive and cause changes to the 
cellular membrane, possibly affecting the budding of functional virus from the host cell 
(personal communication with GTVC). 
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Lentiviral vectors 
Noting the success of previous work using a lentiviral vector to transduce 
myocytes with NaV1.5 [48], we obtained lentiviral plasmid constructs and were able to 
produce lentiviral vectors containing the cardiac sodium channel gene with various 
expression markers. We tested the efficacy of the virus on tsA201 cells and verified 
function of the WT sodium channel by electrophysiological studies. We created lentiviral 
vectors containing the mutant channel R222Q, R814W, or delKPQ and successfully 
verified channel function. Transduction of both guinea pig and rabbit isolated ventricular 
myocytes was possible using lentiviral vectors containing sodium channel genes and the 
marker protein CD8.  
Interestingly, attempts to infect myocytes with lentivirus containing SCN5A and a 
fluorescent marker were unsuccessful, possibly due to low expression of the exogenous 
construct. Because lentivirus is required to integrate into the host cell’s genome and is 
limited to infection by one single virion, expression of lentiviral genes can be 
compromised by the location of insertion into the genome and the amount of transcription 
activity in those genetic regions. It is probable that both guinea pig and rabbit myocytes 
were successfully transduced by viruses containing fluorescent markers, however, 
reduced expression of exogenous marker genes may not have been enough to visually 
identify the small number of fluorescing proteins in the larger cardiomyocyte. By 
expressing a protein on the surface and using an unbiased, antibody interaction, as in the 
case with the Leu2 protein and CD8 antibody coated beads, the CD8 interaction provides 
a more sensitive means of identification of transduced cells. 
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Calcium imaging experiments were performed on healthy, isolated rabbit 
ventricular cardiomyocytes transduced by lentiviral vectors containing WT or mutant 
NaV1.5 channels with the CD8 marker, using the ratiometric dye, Fura-2 AM. We had 
hypothesized that the large influx of sodium during diastole would result in blunting of 
the NCX, causing an increased baseline calcium level, a larger peak calcium transient, 
and an extended time course of the calcium signal as a result of higher sodium 
concentration affecting the function of the NCX. Compared to cells transduced with WT 
channels, there was no overall difference in the change of Fura-2 signal or contraction 
properties recorded from cells exogenously expressing R222Q, R814W, or delKPQ. 
Because we were initially concerned about lower expression from our exogenous 
constructs, we measured sodium currents from transduced myocytes and noted a 
significant decrease in total sodium current in all cells that should be overexpressing 
sodium channels. This is contrary to what we expected; a larger number of channels 
should result in greater current. The decrease in current recorded from transduced 
myocytes may be a direct result of the cell down-regulating native cardiomyocyte 
expression as a result of over-expression of exogenous channels. This is only speculation, 
although, as without another reliable method to determine the amount of exogenous 
channel overexpression in the infected myocytes, it is impossible to identify the degree of 
influence the mutant cardiac channels are having on the function of the myocyte. Because 
of the inconclusive nature of the experiments and results, it is difficult to confirm or deny 
the hypothesis that these cardiac sodium channel mutations induce a heart failure 
phenotype by altering calcium handling in a ventricular cardiomyocyte.  
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CHAPTER IV 
 
SUMMARY AND FUTURE DIRECTIONS 
 
Summary 
 Voltage-gated sodium channels are a diverse group of proteins found throughout 
excitable tissues of the body. Activation of these channels stimulates pore openings and 
allows INa to conduct into the cell. This depolarization of the membrane potential 
produces the initial upstroke of the action potential in most cell types. In cardiac tissue, a 
multitude of currents shape and drive the cardiac action potential and, through the second 
messenger Ca
2+
, contraction is stimulated by EC coupling. Mutations in the cardiac 
sodium channel, NaV1.5, often result in altered action potential morphologies and can 
manifest as arrhythmias, such as long-QT and Brugada syndromes, identifiable on ECG 
recordings. Over the past 10 years, however, a number of mutations in NaV1.5 have been 
discovered that manifest as cardiomyopathies and have encouraged researchers to 
thoroughly examine alternate routes of disease forming mechanisms. 
 In Chapter II, we studied a novel NaV1.5 mutation, R225P, in a patient with 
amiodarone-responsive ventricular ectopy-associated cardiomyopathy. The mutation is 
located in one of the voltage-sensing regions of the channel and mutates one of the 
arginines critical for channel activation. Characterization of NaV1.5-R225P revealed an 
altered activation, resulting in larger, hyperpolarized window- and ramp-currents 
compared to WT channels. The biophysical properties of R225P are similar to previously 
characterized mutations associated with cardiomyopathies (R222Q, R814W) that affect 
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the voltage-sensing regions of NaV1.5. We propose that the hyperpolarized window- and 
ramp-currents are a potential biophysical fingerprint for mutations that could induce a 
heart failure phenotype. 
 Of particular interest, in addition to the activation defects, the mutation R225P 
also exhibits an enhanced slow inactivation resulting in a frequency-dependent decline of 
both peak- and ramp-current. We predict that this could affect the patient at periods of 
higher heart rates, resulting in a decrease of overall INa which negatively effects heart 
function. Examining this mutation in the presence of amiodarone, we showed that the 
R225P mutation is much more sensitive to amiodarone-induced frequency-dependent 
block than WT channels. We believe that amiodarone exacerbates an already enhanced 
slow inactivation and results in a decreased overall pool of mutant channels capable of 
disrupting ion homeostasis and inducing heart failure and this is the means of the 
therapeutic efficacy of the drug.  
 The association of NaV1.5 mutations with cardiomyopathy invites further 
questions on the mechanism for this rare correlation. In Chapter III, we endeavored to 
determine if expression of R814W or R222Q could affect calcium regulation within 
cardiomyocytes expressing the mutant channels. To test this, we explored many options 
for expression of exogenous channels in an isolated ventricular myocyte. Though 
attempts to create an adenovirus carrying the cardiac sodium channel or mutations of 
interest were unsuccessful, we were successful in producing lentiviral vectors capable of 
transducing isolated rabbit ventricular myocytes. 
 Subsequent experiments examining calcium levels in myocytes transduced with 
exogenous NaV1.5 or mutant channels by Fura-2 experiments revealed little to no 
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difference among all the parameters tested. Therefore, we conclude, that in these 
experiments overexpressing exogenous cardiac sodium channels through lentiviral 
transduction of isolated rabbit ventricular myocytes, there is no alteration of calcium 
handling resulting from overexpression of the mutations R222Q or R814W compared to 
WT channels. These experiments, however, are limited to the expression capabilities of 
the lentiviral vector’s ability to transduce a primary cardiomyocyte and the results should 
be confirmed with another method of exogenous channel expression. 
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Future Directions 
 The complexity of diseases associated with mutations of the voltage-gated cardiac 
sodium channel, NaV1.5, is expanding beyond arrhythmia and conduction disorders. The 
recent identification of NaV1.5 mutations associated with cardiomyopathy phenotypes 
creates the necessity to examine the impact of these mutations in a more native cell line. 
The ability to analyze the biophysical properties of sodium channel mutations in a non-
cardiomyocyte cell line, such as tsA201 cells, is critical for identifying functional 
discrepancies within the mutant channel compared to WT. However, in order to 
understand uncommon disease associations, such as cardiomyopathy, it is necessary to go 
beyond channel electrophysiology and examine the impact of mutations on processes of 
the cardiomyocyte, such as calcium signaling and pH regulation. 
 
Heterozygous channel expression 
 The proband with NaV1.5-R225P is heterozygous for the mutation, indicating that 
the wild type allele is also likely expressed. Interestingly, recent work from the lab of 
Isabelle Deschenes, Ph.D., (Case Western Reserve University, Cleveland, OH, USA) has 
indicated that, in co-expression studies designed to mimic the heterozygous setting in 
HEK293, co-expression of WT channels with functionally inactive sodium channel 
mutations associated with BrS can induce unexpected alterations of WT channel activity 
[49]. It has been proposed that α subunits of these channels may be interacting with one 
another and that the mutated channel is exerting a dominant-negative effect. Though the 
scope of these findings pertain to loss-of-function mutations, it would be intriguing to 
examine the resultant biophysical properties of the mutation R225P co-expressed with 
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WT channel in order to recapitulate the heterozygous state of the proband. Because the 
R225P mutation results in activation defects that promote a gain-of-function, we predict 
that the resultant current from co-expression studies would be a hybrid of biophysical 
characteristics already identified in WT and R225P channels. R225P activates at more 
hyperpolarized potentials compared to WT channel, therefore, we hypothesize that the 
ramp-current induced by R225P would still be a dominate feature and would skew the 
activation and combined peaks of the ramp-currents to more negative potentials while 
increasing charge movement. Because all of this is speculation, it would be valuable to 
examine the biophysical properties of R225P in a heterozygous setting. 
 
Transgenic animal model 
 The three mutations, R222Q, R225P, and R814W, all were identified in patients 
with cardiomyopathies. In tsA201 cells, we identified a common defect in the activation 
of these channels that produced large, hyperpolarized ramp currents that we predict will 
introduce excess sodium into the myocyte during diastole and disrupt processes relying 
upon the sodium gradient and indirectly result in a heart failure phenotype. The ideal 
future direction of this work would be to analyze these mutations in a knock-in animal 
model.  
 The first option would be to create a knock-in model capable of expressing the 
respective mutations in an animal with action potential properties and contraction 
characteristics similar to that of human, such as the rabbit. Manipulating the rabbit 
genome in order to answer questions regarding human diseases is an interesting concept 
that has had success over the past decade [50]–[54]. The “knock-in” rabbit technology is 
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still in its infancy, however, advances using zinc finger nucleases to inactivate genes and 
mediate homologous recombination with vector DNA has had initial success in rabbits 
[54]. This opens up the possibilities of creating a rabbit expressing a mutant cardiac 
sodium channel targeted to the locus of an original SCN5A gene copy that would allow 
appropriate biological expression patterns and regulation that is difficult to achieve in a 
transgenic model. Because the rabbit action potential and calcium handling more closely 
mimics that of human, it may yield results that correlate better to what is seen in the 
human disease in terms of the cardiomyopathy-associated sodium channel mutations.  
Another option would be to make a mouse “knock-in” model expressing the 
mutant channels of interest. Though the action potential morphology of the mouse is 
different compared to human or other animals such as rabbit, many successful studies 
have exhibited the validity of the mouse model in relationship to NaV1.5 mutations [55]–
[58].  We predict the cardiomyopathy-associated mutations conduct aberrant INa during 
diastole, resulting in higher [Na
+
]i and altered ion regulation. Regardless of action 
potential properties in the murine system, the myocyte would still need to regulate [Na
+
]i 
in order to maintain proper function. This could result in blunting of the NCX and lead to 
alterations in Ca
2+
 transients, as predicted. However, it is important to note that, in mouse 
and rat, Ca
2+
 removal through NCX is lower and uptake of Ca
2+
  into the SR is greater 
compared to other animal models [59]. Because this mimics what we predict is the 
disease progenitor in human disease, critical analysis of the data would be essential in 
order to determine specific factors related to heart failure. 
 Overall, having a transgenic model, mouse or rabbit, would give access to 
cardiomyocytes stably expressing mutant channels and would remove some of the 
112 
 
variables from the experimental limitations, such as viral production and transduction 
efficiency. We believe this would yield more consistent results and allow for better 
interpretation of the data in regards to our working hypothesis. Using isolated transgenic 
ventricular myocytes, it would be valuable to perform the Fura-2 experiments again, in 
order to verify the data presented here. It would also be interesting to examine pH 
regulation within myocytes expressing the mutant channels. These experiments would be 
done with the ratiometric dye, BCECF, similar to how the experiments for Fura-2 were 
performed. 
 Having an animal model expressing these mutations would also be valuable for 
analysis of therapeutic treatments using animals that may be able to mimic the 
cardiomyopathy identified in human patients. In the case of R225P, the heart failure 
symptoms of the patient are successfully controlled with amiodarone; however, the side 
effects of amiodarone are detrimental and can have lasting consequences.  Quinidine has 
also been shown to have efficacy in treating similar cardiomyopathy phenotypes [24]. 
Though we can speculate a potential therapeutic mechanism for these drugs, it would be 
beneficial to analyze whole heart and cardiomyocyte function in the absence or presence 
of these drugs. Because of the non-specific effects of amiodarone and the deleterious side 
effects associated with the drug, confirming the direct mechanism of action could allow 
the identification of potential pharmaceutical agents with better overall health outcomes. 
 
Induced pluripotent stem cells 
 Induced pluripotent stem cell-derived cardiomyocytes (iPSC-CM) also could 
serve as a valuable tool in examining NaV1.5 mutations associated with heart failure. This 
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relatively novel approach allows the researcher to create an iPSC-CM line derived from 
the patient with the disease phenotype, allowing for a personalized approach to identify 
direct disease mechanisms within the context of an individual’s own genetic framework. 
Direct examination of disease-specific iPSC-CMs has already been shown to be of value 
in multiple instances, including further examination of SCN5A mutations associated with 
long-QT and overlap syndromes [60], [61]. In the case of NaV1.5 heart failure mutations, 
we speculate that the disease is the result of an influx of sodium during diastole that 
disrupts ion homeostasis and results from a continuous insult to individual myocytes. 
Using iPSC-CMs to examine this hypothesis would be ideal, as they have a longer 
usability time in culture compared to isolated ventricular myocytes, which allows the 
cells to be paced for an extended period to recapitulate the probability that these diseases 
develop over time. However, if the mechanism for NaV1.5-induced cardiomyopathy is a 
result of conduction issues, IPSC-CMs may not mimic the complete disease state. Before 
IPSC-CMs become fully reliable as a model system, advances need to be made in 
differentiation techniques, identification methods, and data interpretation [62]. 
 
Clinical implications 
 In Chapter II, we identified another NaV1.5 mutation, R225P, associated with a 
heart failure phenotype. The patient’s condition was able to be controlled with a 
combination of amiodarone and a beta-blocking drug (propranolol or nadolol). Both 
Laurent et al and Mann et al noted in their reports on the cardiomyopathy-associated 
mutation R222Q that patients treated with amiodarone also responded favorably [24], 
[25]. We presented data here on the effect of amiodarone for both WT and R225P, 
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identifying an enhanced inactivation resulting in frequency-dependent block in the 
presence of the drug and identifying a potential mechanism for the therapeutic effect of 
amiodarone. Interestingly, a group of patients with R222Q responded well to treatment 
with quinidine, a drug that has been noted to affect the sodium channel in a use-
dependent manner [24], [63]. Together, the data suggest that both amiodarone and 
quinidine may affect the cardiac sodium channel in the same way and potentially yield 
similar therapeutic benefits. Therefore, we believe that amiodarone treatment or a similar 
drug that blocks frequency-dependent current may be beneficial for patients with a 
cardiac sodium channel-associated cardiomyopathy. 
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